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ABSTRACT 
The gastrointestinal tract is profoundly affected during acute and chronic HIV-1 
infection. Early in the course of the infection, there is a breakdown in gut epithelial barrier 
integrity, high levels of viral replication, CD4 T cell depletion and inflammation in the gut 
mucosa. Importantly, People Living with HIV-1 (PLWH) lose significant numbers of 
protective T helper (Th) 17 and Th 22 populations in the gut. These populations of Th cells 
are essential in promoting epithelial barrier integrity and appropriate immune responses in 
the mucosa. The combined loss of protective Th cell populations and an increase in 
intestinal permeability contributes to the translocation of bacteria and bacterial products from 
the gut lumen into the lamina propria. Microbial translocation (MT) has been linked to 
mucosal and systemic inflammation and is predictive of disease progression and mortality in 
PLWH. The gut microbiome has been shown to influence mucosal immune responses. 
Therefore, its role in HIV-associated mucosal pathogenesis has been a high priority 
research focus. To address the role of the microbiome in HIV-1 associated gut pathogenesis 
and MT, several groups have sequenced the intestinal microbiomes of PLWH. Many of 
these studies have demonstrated a dysbiosis of the microbiome that associates with 
systemic and mucosal inflammation. A key feature of this dysbiosis is the lower relative 
abundance of bacteria that produce the regulatory short-chain fatty acid butyrate. Loss of 
these butyrate-producing bacteria (BPB) species may contribute to the breakdown in gut 
mucosal immune cell homeostasis and systemic inflammation providing a link between 
changes in the microbiome and the host immune response. The mechanisms by which low 
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abundances of butyrate-producing bacteria and likely lower tissue butyrate levels contribute 
to gut mucosal CD4 T cell activation and HIV-1 infection have yet to be determined.  
The purpose of the studies outlined in this thesis was to investigate the importance of 
the findings of decreased BPB species during HIV-1 infection and likely lower tissue 
butyrate levels in an in vitro human gut lamina propria mononuclear cell (LPMC) model of T 
cell activation and infection. This model was used to understand the impact of butyrate on 
enteric bacteria driven T cell activation and HIV-1 infection.  These studies demonstrated 
that butyrate at higher physiologic concentrations decreased enteric bacteria driven LP T 
cell activation, cytokine production, and LP CD4 T cell productive infection.  Next, to address 
the mechanism by which butyrate alters LP CD4 T cell activation and infection, I used an in 
vitro human LPMC model of direct LP CD4 T cell activation and HIV-1 infection. These 
studies determined that butyrate decreased LP CD4 T cell activation, proliferation, and 
cytokine production in a concentration-dependent manner likely through histone deacetylase 
inhibition. In these studies, gut CD4 T cell productive HIV-1 infection in the setting of CD4 T 
cell activation was decreased at higher concentrations but increased at lower concentrations 
of butyrate likely through increased CCR5 expression and increased viral entry/reverse 
transcription. The findings outlined in this study suggest that the low abundance of mucosal 
butyrate-producing bacteria and the likely low tissue butyrate levels that occur in the setting 
of chronic HIV-1 infection may potentiate LP CD4 T cell infection, contribute to chronic 
immune activation and therefore might be a contributing factor in HIV-1 disease 
pathogenesis. 
The form and content of the abstract are approved. I recommend its publication. 
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HIV-1 Infection: Epidemiology 
 
 The retrovirus human immunodeficiency virus type 1 (HIV-1) that causes acquired 
immunodeficiency syndrome (AIDS) has been a global health epidemic for over 30 years 
and continues to be one of the primary causes of mortality and morbidity worldwide[1]. 
According to the World Health Organization’s (WHO) most recent data, as of 2017, there 
have been more than 70 million known infections and at least 35 million individuals who 
have died due to HIV-1 related illnesses. HIV-1 prevalence is higher in several groups such 
as intravenous drug users, men who have sex with men (MSM), sex workers and those with 
barriers to care such as those who are incarcerated and that lack access to medical care. 
While there are significant global populations of persons living with HIV-1 (PLWH), there is a 
wide prevalence of HIV-1 infection in many of the countries in western, central, eastern and 
southern Africa where the highest burdens of HIV-1 infection exist[1]. 
The WHO notes that there are currently 36.9 million PLWH and nearly 1 million 
individuals succumbed to HIV-1 related illnesses in 2017, and many of those individuals are 
in developing countries, where there are barriers to the access to adequate care and 
medical education[1]. Notably, the WHO has stated nearly 4% of adults in Africa are infected 
with HIV-1, which represents 2/3 of total global HIV-1 infections.  The introduction of 
antiretroviral therapy (ART) has resulted in a dramatic decline in the incidence of HIV-1 
related illnesses and deaths[1, 2] through the decrease in HIV-1 viral load[3] and thus CD4 
T cell loss[3, 4]. Adherence to ART has resulted in an increased lifespan of PLWH and 
decreased the incidence of new infections as individuals who are virally suppressed are 
unlikely to infect others[5, 6]. Recently, ART based pre-exposure prophylaxis (PreP), has 
been approved for individuals at risk of HIV-1 infection and has been shown to decrease 
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HIV-1 transmission in adherent individualseffectively[7-9]. It is clear from the continued 
prevalence of HIV-1 that there is a need for additional treatments and better access to 
adequate medical care and education to quell the HIV-1 epidemic[1, 7]. 
HIV-1 Infection: The Virus, Life Cycle, and ART 
 
 The HIV-1 virus belongs to the genus Lentivirus, family Retroviridae and subfamily 
Orthoretrovirinae[8].  Within each mature viral particle, there are two identical single strands 
of RNA (ssRNA) that are contained within a viral core protein[8, 9]. The viral genome is 
flanked by long terminal repeat sequences (LTR) that contain the essential promoter regions 
for viral transcription. The three primary structural genes are gag (group-specific antigen), 
pol (polymerase) and env (envelope glycoprotein). The proteins encoded by gag consist of 
the outer core membrane (p17), the capsid protein (p24) and the nucleocapsid (p7) while pol 
codes for the enzymes protease (p12), reverse transcriptase (p51), RNase H (p15) and 
integrase (p32). Lastly, env codes for the two envelope glycoproteins gp120 and gp41[8-10]. 
The HIV-1 genome also codes for several accessory proteins that include Tat and Rev, 
which help in the initiation of HIV-1 replication from integrated viral DNA and export of viral 
transcripts from the nucleous[8-10]. There are also several regulatory proteins that help the 
virus evade host immune responses, which include Nef, Vif, Vpr and Vpu [8, 9].  
The HIV-1 viral life cycle begins with the high-affinity binding of HIV-1 envelope 
protein gp120 to CD4 on the cell surface[11, 12].  This interaction is necessary but not 
sufficient for viral entry, which requires subsequent contact of gp120 with a co-receptor. HIV-
1 co-receptors are the G-protein coupled chemokine receptors CCR5 and CXCR4[13-16]. 
Viral tropism predicts which co-receptors gp120 interacts with during infection. Initially, most 
of the transmitted viruses have tropism for CCR5 while later in advanced disease there is a 
shift to CXCR4 tropism[16-19]. The binding of HIV-1 gp120 to CD4 and the co-receptor 
elicits a conformational change in the viral envelope proteins driving fusion of the virus and 
target cell[20, 21]. Once inside the cell endosome, the viral capsid contents are released 
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into the cytoplasm[8, 10, 22]. The viral protein reverse transcriptase (RT) then transcribes 
the single-stranded HIV-1 RNA into complementary DNA (cDNA). During the early steps of 
reverse transcription, two template switches occur. These involve the transfer of both minus 
and plus strand strong stop DNA (RU5 sequence) facilitating the production of viral DNA[8, 
22, 23]. While cDNA is being synthesized, the viral RNA is degraded by the viral enzyme 
RNase H. Next, the single-stranded cDNA is converted into double-stranded DNA by 
reverse transcriptase’s DNA dependent DNA polymerase activity. HIV-1 DNA is then 
transported into the cell nucleus by the viral protein integrase which also acts to insert the 
viral DNA throughout the human host cell genome[10, 22, 24]. Once the viral DNA has 
undergone integration, the cell can either remain latently infected or the viral genome can be 
transcribed during cell division or activation. During transcription, the long terminal repeat 
(LTR) promoter of the viral genome serves as a docking site for host cellular DNA 
dependent RNA polymerases along with the viral protein tat and other transcription factors 
that drive the synthesis of viral mRNA. After splicing of the viral RNA and translation, viral 
proteins along with the Gag-Pol precursor polypeptides are packed into nascent virions and 
bud out of the cell into the extracellular space through the host cell membrane[10, 22, 24]. 
Once this process is complete, the viral protein protease cleaves the Gag-Pol peptides 
forming the mature infectious virion[10, 22, 24].  
Over the last 20 years, there have been several pharmacological advances in the 
treatment of HIV-1 infection. Most important of these are ART advances that target essential 
components of the HIV-1 life cycle. The first approved drug for the treatment of HIV-1 was a 
nucleoside reverse transcriptase inhibitor (NRTI), zidovudine[2, 25], which functions by 
targeting RT and interrupting the elongation of the viral DNA chain produced by RT[2, 26]. 
This drug, along with other nucleoside or nucleotide reverse transcription inhibitors, is a pro-
drug that is phosphorylated by cellular enzymes once in the cell to become the active drug. 
They are taken up by RT due to their similarity to cellular nucleotides but stop the elongation 
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of the DNA chain due to competitive inhibition of cellular nucleotides in a process called 
chain termination[2, 26]. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are 
another class of ART that target RT but do so by directly altering RT protein conformation 
and inhibiting its function[2, 27]. These drugs bind to RT outside of the active site and 
function through non-competitive inhibition. The next class of ART target the viral protease, 
which prevents the maturation and production of HIV-1 virions by interrupting the function of 
the viral protease protein[2, 28].  The integration of the HIV-1 genome into the host cell can 
also be disrupted by targeting viral integrase with integrase strand transfer inhibitors 
(INSTIs) such as raltegravir[29]. This class of drugs blocks integrase from catalyzing the 
formation of bonds between the host and viral DNA, thus preventing the incorporation of 
viral DNA into the human genome[2, 29]. Lastly, there are drugs, termed entry inhibitors, 
that have been developed to block the interaction of HIV-1 with CCR5 (maraviroc)[30]. 
Furthermore, there is a class of fusion inhibitors that prevent the fusion of the virus with the 
target cell, such as Enfuvirtide[2, 31]. While these drugs are very effective at halting HIV-1 
infection, they must be used in combination due to the ability of the virus to rapidly mutate 
and become resistant to individual drugs. Therefore most ART combinations in use have a 
combination of NRTI/NNRTI and another ART class or  2NRTI+NNRTI[2]. 
HIV-1 Infection: Pathogenesis 
 HIV-1 is transmitted through breaches in the mucosal or epidermal barriers, 
intravenous introduction or vertically from mother to child either in utero, during delivery or 
breast feeding[22]. During the initial transmission event, it is thought that single virions are 
responsible for establishing an infection. The virus that transmits the infection is known as a 
transmitted founder virus (TF), which through variance in glycosylation and amount of Env 
make them more infectious and adept at binding to HIV-1 receptors (CD4 and primarily 
CCR5) and bind better to dendritic cells. Furthermore, these TF viruses can evade host anti-
viral immunity such as the type I interferon responses[18, 19, 32]. Once introduced into the 
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body, the free virus can infect CD4 T cells or be taken up and disseminated by dendritic 
cells (DC), which then infect CD4 T cells by trans-infection[33-35]. Regardless of the site of 
infection, HIV-1 rapidly replicates in and depletes the CD4 T cell populations throughout the 
body[36-41], particularly in the gastrointestinal (GI) tract mucosa[36, 40-45] which is likely 
due to the high abundance of CCR5+ effector memory CD4 T cells at this site[46]. During 
the acute phase of the infection, there is rapid dissemination of the virus as determined by 
increases in viral load in the systemic vascular circulation and the infection and depletion of 
peripheral blood (PB) CD4 T cells[47]. In addition to the loss in CD4 T cells, there is an 
increase in immune cell activation as characterized by increased frequencies of activated 
CD8[48-50] and CD4 T cells (as determined by CD38 and HLA-DR expression)[50-52], 
circulating pro-inflammatory cytokines[53-56] and innate immune cell activation 
systemically[47, 55, 57, 58]. Notably, the increase in peripheral CD8 T cell activation has 
been associated with HIV-1 disease progression and mortality in PLWH[50, 51, 59]. Over 
the weeks and months following the acute phase of the infection, there is a detectable 
rebound in CD4 T cell populations in the periphery, an increase in HIV-1 reactive antibodies, 
a moderate decrease in immune activation and the establishment of a viral set point (a 
steady state viral load)[47, 60]. This period is characterized as the chronic phase of the 
infection. If left untreated these individuals can eventually progress to acquired 
immunodeficiency syndrome (AIDS), characterized by low CD4 T cell counts (below 200 
cells/ul), CD4 T cell percentage of total lymphocytes ≤ 14% or the presence of an AIDS-
defining illness. At this point in the disease progression, the individual becomes susceptible 










Figure 1.1. HIV-1 Viral Life Cycle and the Sites of Action of ART. HIV-1 infection begins 
with the attachment of the virus to the cell host proteins CD4 and CCR5/CXCR4 and 
subsequent fusion with the cell membrane. This process can be blocked by fusion and 
CCR5 inhibitors (1,2). The next primary target in the HIV-1 life cycle is Reverse 
Transcription, which there are several reverse transcriptase inhibitors (NRTI or NNRTIs) (3). 
The viral genome is then packaged and integrated into the host genome by the enzyme 
integrase which can be inhibited by integrase strand transfer inhibitors(4). Lastly, the 
nascent viral particles are released from the cell, and the viral protein protease cleaves the 
viral proteins forming the mature virion. This process can be inhibited by protease 
inhibitors(7). Figure and legend adapted from https://www.niaid.nih.gov/diseases-








HIV-1 Infection: Mucosal Immune Response 
 
Mucosal Immunity in Health 
 
 The GI tract mucosal barrier is an essential defense against pathogens and plays a 
role in the tolerization of the immune system to commensal bacteria and food antigens[62-
64]. The cells most intimately associated with the gut lumen are the epithelial cells, which 
have various roles that range from nutrient uptake in the small intestine, production of 
antimicrobial proteins, transport and secretion of IgA antibodies, mucin production by 
goblets cells, water absorption in the colon and a barrier to commensal and pathogenic 
microbes[63-65]. Gut epithelial cells are essential regulators of the mucosal immune 
response through the production of cytokines and other factors when they encounter both 
commensal and pathogenic microbes[64, 65]. Within the epithelial layer, there are dendritic 
cells that sample the gut lumen, and several adaptive immune cell subsets termed 
intraepithelial lymphocytes (IEL)[66, 67]. The IEL fraction of cells is comprised of Mucosal-
associated invariant T (MAIT) cells, which respond to conserved microbial antigens, along 
with CD8 αα and αβ T cells as well as γδ and small populations CD4 T cells[66, 67].  
Basolateral to the epithelial barrier lies the lamina propria (LP) and immunological inductive 
sites such as Peyer's Patch in the small intestine or tertiary inductive sites which are found 
throughout the GI tract[68]. Specifically, the LP is comprised of various mononuclear cells 
(LPMC) that include myeloid DCs (mDC), T helper (Th) CD4 T cells, CD8 T cells, γδ T cells, 
NK cells, innate lymphoid cells(ILCs), B cells, macrophages, mast cells and during 
inflammation neutrophils and plasmacytoid DCs (pDCs)[62, 63, 68-72]. In health these cells 
work in concert to promote epithelial barrier integrity and function through the production of 
pro-barrier forming cytokines such IL-22[73], which functions in part through the promotion 
of stem-cell mediated proliferation of epithelial cells and the induction of antimicrobial 
peptides by the epithelium [42, 62, 64, 65, 70, 74].  
8 
 
 The lamina propria of the gut is densely populated with CD4 T helper cells. These 
cells are largely comprised of Th1, Th17 and Th22 cells with lower frequencies of Th2 and T 
regulatory cells[75]. These cells play an essential role in the defense against pathogens and 
maintenance of the epithelial barrier. The majority of the Th cells in the mucosa are Th1 
cells[75], which respond to activation and antigen presentation by producing cytokines such 
IFNγ and the express the transcription factor Tbet[76]. The other Th subsets are present in 
the gut mucosa at much lower frequencies. The Th17 cells mainly produce IL-17 but can be 
polyfunctional and produce IFNγ and IL-22 and are characterized by the expression of the 
transcription factor RORγt[76]. The Th22 cells mainly produce IL-22 and express the 
transcription factor AHR[76]. The T regulatory cells produce multiple regulatory cytokines 
such as IL-10 and TGFβ and are largely characterized by the expression of the transcription 
factor FOXP3[76].  Lastly, Th2 cells are characterized by the expression of GATA3 and 
produce cytokines such as IL-4 and IL-13 which are essential in the defense against 
parasitic infections[76]. While these cells have unique roles in the gut mucosa, they share 
several similarities in the mechanisms by which they are activated as well as in their 
phenotype. 
 In general, there are several conserved steps in CD4 T cell activation which can be 
broken into three signals. The first signal consists of antigen presentation from antigen 
presenting cells (APCs) such as dendritic cells, macrophages, and B cells[77]. These cells 
take up antigen and process it into peptides that are presented in the major 
histocompatibility complex II (MHC)II. Once presented, this antigen is recognized by the T 
cell receptor (TCR), which in most CD4 T cells consist of α and β chains that have 
undergone sequence recombination (V-D-J (β) and V-J(α)) to recognize specific peptides 
presented by MHCII[77]. While this signal is important for T cell activation it is not sufficient. 
The second signal that is involved in CD4 T cell activation is the engagement of co-
stimulatory molecules on the cell surface, such as CD28, by co-stimulatory proteins on the 
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APC surface such as CD80 and CD86[77]. In addition to the activation of CD4 T cells 
through CD28, several other surface molecules alter T cell activation, such as OX40 and 
CTLA-4[78]. The combination of these two signals is thought to be the primary mechanism 
by which CD4 T cells are activated. The exposure of CD4 T cells to cytokines, such as IFNγ 
and IL-2, is considered to be a third signal that drives CD4 T cell activation and proliferation 
as well as differentiation in naïve CD4 T cells[79]. The culmination of these signaling events 
at the cell surface drive intracellular changes such as the activation of the transcription 
factors NF-κB and AP-1 and increases in cytosolic calcium concentrations which then 
activate calcineurin and ultimately promote the activity of transcription factor NFAT[78]. The 
combination of the activation of these transcription factors drives CD4 T cell activation and 
proliferation.  
 The Th cells that reside in the gut mucosa have recently been described to have a 
unique phenotype and function relative to other Th subsets in the periphery and are 
primarily considered tissue-resident memory (TRM) CD4 T cells[80, 81]. These cells are 
resident in the mucosa and are generated in the mesenteric lymph nodes when APCs 
present gut-derived antigens[82]. These T cells can respond rapidly to antigen presentation 
and produce cytokines such as IL-17 and IFNγ[82, 83]. Phenotypically, they differ from the 
memory T cells in the peripheral circulation in that they have an effector memory phenotype 
(CD45RO+CD62L low) and have high expression of CD69 (a marker of acute activation in 
other CD4 T cell populations) and lower expression of S1P1(sphingosine 1-phosphate 
receptor)[80, 82]. CD69 is typically upregulated on CD4 T cells early during activation when 
the cell needs to be sequestered, such as in an inductive site (i.e., lymph nodes). S1P1 
expression on T cells allows them to egress and access the peripheral circulation after 
education in lymph nodes[84].  Therefore, there are likely signals in the mucosa driving the 
expression of these markers.  The idea of gut-specific signals driving the expression of 
CD69 on human CD4 T cells is supported by the observations in Bolduc et al. [85], who 
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noted that the bacterial metabolite acetate, which is found at high concentrations in the gut 
lumen, promoted the expression of CD69 on CD4 T  cells.   
Intestinal CD4 T cells are uniquely poised to interface with commensal and 
pathogenic bacteria, metabolites and food antigens found in the gut lumen. Several studies 
in mice have outlined how commensal and pathogenic bacteria play an essential role in the 
differentiation and maintenance of both Th17 and T regulatory cells in the gut mucosa[86-
90]. In an elegant study by Ivanov et al. [91], colonization of the murine small intestine with 
segmented filamentous bacteria (SFB) induced the differentiation of Th17 cells in the lamina 
propria and protected these mice from Citrobacter rodentium infection, a murine gut 
pathogen. While the mechanism of SFB driven Th17 differentiation has yet to be fully 
understood, several studies have indicated a role for antigen presentation from myeloid 
cells[86, 87]. Commensal gut bacteria have also been shown to drive T regulatory cell 
differentiation and function (IL-10 production and inhibitory capacity) in the murine gut 
mucosa. Specifically, bacteria from clusters IV and XIVa of the genus Clostridium and 
Bacteroides fragilis have both been shown to induce the differentiation and function of these 
cells in the murine colonic mucosa and human in vitro studies[88-90]. While findings have 
yet to be fully replicated in in vivo human studies, they clearly outline a unique and essential 
relationship between the microbiota and CD4 T helper cell differentiation and responses. 
Mucosal Immunity in HIV-1 Infection 
 
There are early changes in the mucosa during the acute phase of HIV-1 infection in 
PLWH[36, 44, 45]. However, it is technically challenging to study the immediate (hours-
days)  changes in the mucosa after initial infection with HIV-1 in humans. To extensively 
investigate this issue, several groups have used the primate homolog virus simian 
immunodeficiency virus (SIV) to characterize the initial events in infection. These studies 
have given insight into the rapidity of the infection, disruption of the epithelial barrier and 
depletion of the gut mucosal CD4 T cells [47, 92-95]. While the immunological events that 
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occur during SIVmac infection have been well characterized, the detailed kinetics of these 
events until recently had not been fully characterized.  In an elegant study by Hensley-
McBain et al. [93], the kinetics of mucosal and systemic immune responses during 
pathogenic SIV infection were evaluated. An important finding from this study was that 
epithelial barrier integrity was lost early during infection (roughly three days). They 
determined by proteomic analysis that by three days post-infection there were significant 
decreases in proteins involved in cadherin-mediated cell to cell adhesion. Conversely, the 
changes in the immune response were not noted until nearly 14 days post infection. This 
observation that the epithelium was altered very early was consistent with a previous study 
that demonstrated the Paneth cells in the colon sensed SIV virus and produced IL-1β before 
an interferon-based antiviral response was detected and the production of IL-1β was 
associated with epithelial barrier disruption[94]. While the initial kinetics of epithelial barrier 
breakdown is less well studied in HIV-1, several studies have noted disruption of the 
epithelial barrier by the presence of breakdown products of the epithelium and alterations in 
tight junction proteins during HIV-1 infection[96-99]. Collectively, these studies demonstrate 
that a rapid and dramatic loss in epithelial barrier integrity precedes the loss of gut mucosal 
CD4 T cells and immune cell activation and likely contributes to the increased microbial 
translocation (MT) noted in both SIV and HIV-1 infections. The increase in MT has been 
detected in PLWH by increases in serum LPS, LTA, 16srRNA and downstream indicators of 
bacterial component interaction with the innate immune system (soluble CD14) [100-106]. 
These indicators of MT are associated with disease progression[107] and increased 
systemic inflammation in PLWH[100, 101, 104, 105] and persist despite viral suppression on 
ART[108, 109].  
There is significant activation and dysregulation of the gut mucosal immune system 
during HIV-1 infection[37, 40, 43, 45, 57, 69, 71, 103, 106, 110-112].  One population of gut 
immune cells that are dramatically altered during HIV-1 infection is the CD4 T helper (Th) 
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cells in the LP throughout the GI tract. These cells are important regulators of epithelial cell 
function and provide defense against pathogens.  They express high levels of HIV-1 co-
receptor CCR5 and are more readily infected than their counterparts in the periphery[46, 
113]. During HIV-1 infection, there is a preferential depletion of the Th17[37, 43] and 
Th22[114] cells in the gut mucosa of PLWH. The importance of these Th populations in the 
gut mucosa is highlighted by individuals known as long-term non-progressors who are 
infected but able to control the HIV-1 virus in the absence of ART  and appear to preserve 
their Th17 populations both in the gut and in the periphery[115, 116]. Furthermore, in the 
nonpathogenic SIV model, where monkeys (Sooty Mangabeys and African Green Monkeys) 
that are infected with SIV but remain asymptotic and do not progress to AIDS[117], there is 
a preservation of the Th17 cells in the mucosa and periphery[43, 118] unlike in the 
pathogenic SIV model where there is a marked decrease in these populations[118-120]. 
Together these observations indicate that the loss of these cells is of central importance to 
the progression of HIV-1. To further understand the importance of Th17 populations and the 
progression of HIV-1 there have been several in vitro studies carried out. These studies 
demonstrated increased frequencies of Th17 infection relative to other Th subsets through 
various mechanisms, including a lack regulatory RNAses that limit HIV-1 infection [121], 
higher expression of α4β7 [122],  higher frequency of CCR5+ cells and production of lower 
amounts of CCR5 ligands(MIP1-α/β) [123], increased mTOR phosphorylation[124] and lastly 
increased presence of several intracellular proteins shown to make cells more permissive to 
HIV-1 infection [125]. From these studies, it is clear that the mechanism by which Th17 cells 
are preferentially infected and depleted in vitro is likely multifaceted and needs further 
investigation.  
In addition to changes in the Th populations, there are also alterations in other 
adaptive and innate immune responses. Several studies have demonstrated that PLWH 
have an increased frequency of activated myeloid DCs [57], pDCs [71], neutrophils [126, 
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127] as well as increased inflammatory cytokines such as type I interferons[127, 128]. Along 
with these changes, there is a further dysregulation of the adaptive immune response in the 
gut mucosa characterized by dysregulation of B cell function and antibody production[129] 
and the increased frequency and altered activation of CD8 T cells (Figure 1.2).  
The Role of the Gut Microbiome in HIV-1 Infection 
The human gut microbiome consists of a diverse and vast population of bacteria, and 
other microbes such as fungi that are thought to be equally if not more abundant than host 
somatic cells[130]. In the last decade, there has been a multitude of studies examining the 
composition of the bacteria that co-exist with humans and how those populations vary by 
location,  change during development and disease as well as the differences that arise from 
the environment, lifestyle and diet[130]. To date, much of the focus of these studies has 
been on those commensal bacteria found in the GI tract, particularly the stool. The gut 
microbiome, which is thought to be on the magnitude of 1x1012, plays a vital role in the 
digestion of starches and other nutrients and is integrally tied to both mucosal and systemic 
health[130]. Numerous studies have identified perturbations in the composition and diversity 
of the GI tract microbiome and found associations with these changes in a variety of human 
disease states, which include atherosclerosis[131], septic shock[132], obesity[133], 
IBD[134-137] and psychological disorders such as anorexia nervosa[138] and autism[139].  
Importantly, the microbiome is critical in shaping the immune system at mucosal and barrier 
surfaces. It has been demonstrated that early colonization of the gut lumen is essential in 
the formation of immune tolerance and epithelial barrier integrity[140, 141]. Furthermore, 
interruption of this normal development with treatments such as broad-spectrum antibiotics 
can result in an imbalance of immune cell activation and tolerance driving autoimmune 





Figure 1.2. The Gut Mucosal Immune Response During HIV-1 Infection.  There are 
several hallmarks of HIV-1 infection in the gut mucosa. The breakdown of the epithelial 
barrier and subsequent microbial translocation(MT) have been noted to occur to HIV-1 
infection (1). There is also an increase in the frequency of activated innate immune cells 
(e.g., mDCs) and CD4 and CD8 T cells (2-4). Importantly, the CD4 T cell populations are 
found to be activated, infected and decreased in frequency (3). Lastly, there is also a 
dysbiosis of the colonic mucosal and stool microbiomes in PLWH (5). Figure adapted from 









To address a potential link between the composition of the GI tract microbiome and 
the mucosal and systemic inflammation seen during HIV-1 infection, several studies have 
sequenced the 16S ribosomal RNA (rRNA) of the fecal and mucosal microbiomes in 
PLWH[101, 103, 111, 145-154]. In both treated and untreated PLWH, there is evidence of a 
reduction in alpha diversity, a measure of bacterial taxa diversity within an individual, of the 
bacterial populations in the GI tract[145-148, 150]. Although, there have also been reports of 
no changes[101, 103, 111, 151, 152] or increases[149, 155] in alpha diversity as well. 
Several of the early studies on the GI tract microbiome in PLWH noted consistent alterations 
in the composition of the microbiome, with increases in several Gram-negative bacteria, 
many with known proinflammatory potential such as Prevotella,[101, 103, 111, 146, 148, 
149, 151, 152] and decreases in Bacteroides and several Gram-positive bacteria, many that 
contain regulatory bacteria such as families and genera that include butyrate-producing 
bacteria (BPB) species, such as Lachnospiraceae and Ruminococcaceae [103, 111, 145-
148, 150, 151, 153, 154].  In addition to HIV-1 infection, the lower relative abundance of 
butyrate-producing bacteria (BPB) such as those belonging to the genera Roseburia and 
Faecalibacterium have been characterized in other inflammatory diseases of the colonic 
mucosa such as Crohn’s disease and ulcerative colitis[135-137]. Therefore, there is an 
association with the loss of these bacteria and gut inflammation. A study undertaken by 
Dillon et al. [103] characterized the colonic mucosal microbiome of untreated PLWH. They 
demonstrated that there was an HIV-1 associated dysbiosis of the composition of the 
colonic microbiome that included an increased relative abundance of Gram-negative 
bacteria along with a lower relative abundance of bacteria in the Firmicutes phylum including 
Lachnospiraceae and Ruminococcaceae. Subsequently, they demonstrated that the Gram-
negative enteric bacteria increased in the microbiome of chronically infected and untreated 
PLWH, can increase HIV-1 infection in an in vitro intestinal cell model of MT and this was 
mediated by increased expression of CCR5 on LP CD4 T cells[156] (Figure 1.2).  While 
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there is an important association of the gut microbiome and HIV-1 infection, recent studies 
have demonstrated that the men who have sex with men (MSM) lifestyle may also contribute 
to changes in the fecal microbiome. The MSM lifestyle is thought to be responsible for the 
noted increased relative abundance of Prevotella in many studies when HIV-1 infected study 
participants are not matched for sexual behavior[155, 157-159]. The first of these studies 
carried out by Noguera-Julian et al. [160] examined the fecal microbiome of HIV-1 infected 
and uninfected individuals and controlled for MSM status. Their studies demonstrated that 
the fecal microbiomes of their study participants clustered by MSM (Prevotella) and non-
MSM (Bacteroides) lifestyle rather than by HIV-1 serostatus. There have been several follow 
up studies, which have demonstrated a similar Prevotella rich fecal microbiome in MSM[155] 
and mucosal microbiomes of individuals who participate in condomless receptive anal 
intercourse[158]. Importantly, in a study where MSM status was controlled for in a group of 
PLWH[155], the relative abundances of stool species BPB, such as Faecalibacterium 
prausnitzii, as well as families and genera that contain BPB were negatively associated with 
blood T cell activation and microbial translocation.  Therefore BPB relative abundance may 
still play a role In the regulation of inflammation in PLWH. 
Short Chain Fatty Acids 
One crucial component of the microbiome is the production of metabolites from the 
breakdown of ingested starches and proteins. Short chain fatty acids (SCFAs) are metabolic 
end products of the fermentation of indigestible carbohydrates and in some cases the 
metabolism of amino acids and peptides by the anaerobic bacteria that colonize the GI 
tract[161-165].  The primary SCFAs are acetate, propionate, and butyrate, which are 
present in the lumen of the human colon in a 60:20:20 molar ratio with total levels averaging 
100 millimolar (mM) [161-165]. In studies of the human GI tract, SCFAs are present in the 
gut lumen, portal and systemic circulation[166, 167]. From these studies it is clear that large 
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amounts of SCFA are metabolized crossing the colonic epithelial barrier from the gut 
lumen(acetate: 53mM, propionate: 20 mM and butyrate: 20 mM), which is reflected in the log 
fold decreases of these SCFA in the portal circulation(acetate:258 µM, propionate:88 µM 
and butyrate: 30 µM) from the gut lumen. After passing through the liver, the concentrations 
of SCFA are further diminished in the systemic circulation with acetate (70 µM) remaining 
the highest while propionate (5 µM) and butyrate(4 µM) only present at trace to non-
detectable levels[166, 167]. Acetate is a net metabolic end product of most anaerobic 
bacteria in the GI tract and is typically generated via two pathways. The most common route 
is starch fermentation by most anaerobic bacteria in the colon. The next pathway is specific 
to acetogenic bacteria, that synthesize acetate from free hydrogen and carbon dioxide in the 
gut lumen or from formic acid through the Wood–Ljungdahl pathway[162]. Propionate is 
produced by bacterial species in the Bacteroidetes and Firmicutes phyla through succinate, 
propanediol or acrylate metabolic pathways with the succinate pathway being 
dominant[162].  Butyrate is produced via two dominate pathways, the butyryl-CoA: acetate 
CoA-transferase and butyrate kinase pathways[162, 168-170]. The butyryl-CoA: acetate 
CoA-transferase pathway is the dominant pathway where butyryl-CoA is converted to 
butyrate in a single step. This pathway is the primary pathway used by BPB in the 
Firmicutes phylum, such as those in the Roseburia, Faecalibacterium and Eubacterium 
genera. The less common route of butyrate production is via the butyrate kinase pathway 
mostly found to be used in Coprococcus species (Table 1.1) [162, 168-170].  These SCFAs 
serve multiple roles in the bacterial communities in which are produced, including altering 
the microenvironment by changing the pH and acting as a source of energy for other 
bacteria when they are metabolized in a process known as cross feeding[162, 164]. Lastly, 
they have essential roles in human GI tract health with microbial-derived butyrate acting as 
a significant energy source for colonic enterocytes and an important modulator of epithelial 










Bacteria Species SCFA produced Metabolic Pathways 
Anaerostipes_caccae Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Anaerostipes_hadrus Butyrate butyryl‐CoA:acetate CoA‐
transferase 





transferase;  acrylate pathway 
Coprococcus_eutactus Butyrate Butyrate Kinase 






Eubacterium_rectale Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Roseburia_faecis Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Roseburia_hominis Butyrate butyryl‐CoA:acetate CoA‐
transferase 







Anaerotruncus_colihominis Butyrate Not Determined 
Faecalibacterium_prausnitzii Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Subdoligranulum_variabile Butyrate Butyrate Kinase 
Eubacterium_biforme Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Eubacterium_cylindroides Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Odoribacter_splanchnicus Butyrate Amine metabolism 
Clostridium_botulinum Butyrate Butyrate Kinase 
Butyrivibrio_crossotus Butyrate Butyrate Kinase 
Butyrivibrio_fibrisolvens Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Butyrivibrio_proteoclasticus Butyrate butyryl‐CoA:acetate CoA‐
transferase 
Clostridium_saccharolyticum Butyrate butyryl‐CoA:acetate CoA‐
transferase 




SCFA Mechanisms of Action 
Histone Deacetylase Inhibition 
In addition to the typical regulation of gene transcription by transcription factors, 
epigenetic modifications of both DNA and the nucleosome play an important role in the 
regulation of gene expression[175, 176]. Nucleosomes are structural units of chromatin that 
consist of DNA and the scaffolding histone proteins. Within this structural unit, epigenetic 
modifications can be made to both the DNA and the histone proteins[175, 176]. Histone 
modifications (i.e., acetylation) play an important role in the regulation of mammalian gene 
expression[175, 176]. One of the primary modifications of histones is the addition of acetate 
to lysine residues in the N-terminal of the core histone proteins (H2A, H2B, H3, H4)[175-
177]. In total there are potentially more than 28 sites where these modifications can occur 
on the N-terminal tail histones. The addition of acetyl groups is primarily carried out by 
histone acetyltransferases (HAT) proteins[175-177]. Histone deacetylase (HDAC) proteins 
function by removing acetyl groups from histone tails. There are in total of four classes of 
HDACS ( I, IIa, IIb, III, and IV)[177-180]. These HDAC classes have individual properties 
and cellular locations, which allow them to uniquely impact chromatin state, gene expression 
and protein function[177-180].  The HDAC proteins are targets of both naturally occurring 
and small molecule inhibitors, which are termed Histone Deacetylase inhibitors (HDACi). 
HDACi act by inhibition of the enzymatic activity of HDAC proteins and therefore promote 
the hyperacetylation of histone tails and the open state of chromatin which is due to both the 
inhibition of the HDAC proteins as well as the continued activity of the HAT proteins[177-
180].  
The acetylation of histones is known to impact gene expression. When promoter 
DNA is assembled onto a nucleosome that is hypoacetylated, transcription factors cannot 
bind and initiate transcription, which is likely due to the positive charge of the N-terminal 
lysines that interacts strongly with DNA phosphates and promotes tight coiling of the DNA 
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into heterochromatin[175-177]. Conversely, in most cases when the histones are acetylated 
at their N-terminal lysine residues they no longer actively interact with DNA and surrounding 
proteins allowing access to the DNA and transcription[175-177]. 
Butyrate, propionate and more recently acetate have been characterized as HDAC 
inhibitors (HDACi) with the ability to inhibit both class I and II HDAC proteins[85, 180-183]. 
Butyrate is an aliphatic acid that is a relatively weak HDAC inhibitor with activity in the 
millimolar range[180]. Butyrate targets and inhibits a large group of HDACs but does not 
have activity on HDAC-6, HDAC-10 and class III and IV HDACs[180, 181]. To act 
intracellularly, butyrate must be either transported by surface transporters MCT-1 or 
SLC5A8, which are not specific for butyrate[184, 185] or likely diffuse through the plasma 
membrane. The mechanism of action of butyrate’s HDACi is as a noncompetitive inhibitor, 
which implies that butyrate binds to a unique site on the HDAC proteins to inhibit the 
enzyme’s function[180]. Interestingly, there appears to be a sequence-specific regulation of 
individual genes by butyrate due to the presence of a common DNA sequence that is 
believed to be a butyrate response element[186, 187]. Through its HDACi activity, butyrate 
has been shown to regulate a multitude of genes and cellular processes that include 
components of the mTOR pathway[188, 189], cell cycle progression [186, 187], 
proliferation[187, 190-192], activation[192, 193] and cell differentiation[187, 194-197] 
(Figure 1.3). 
G-protein Coupled Receptor and PPARγ Signaling 
GPCRs are a diverse and abundant class of seven transmembrane spanning 
proteins, which are crucial in the regulation of a variety of cellular functions. GPCRs have a 
varied distribution of expression in the body and can be regulated by multiple stimuli. These 
receptors signal internally through heterotrimeric G-proteins that are made up of either 
α(Gαs, Gαi, Gαq, and Gα12), β, and γ subunits[198, 199]. The primary SCFA receptors are 
GPR41, GPR43 and GPR109a, of which GPR109a is specific to both butyrate and niacin, 
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whereas GPR41 and GPR43 can be activated by any of the three primary SCFA[200-204]. 
GPR43 has an affinity for the smaller SCFA such as acetate and propionate while GPR41 
preferentially binds larger SCFA (propionate and butyrate) and has a lower affinity for 
acetate[200-205]. GPR41, GPR43, and GPR109a have been demonstrated to be expressed 
on a multitude of human tissue, including human immune cells such as neutrophils and 
monocytes. During signaling GPR109a and GPR41 couple to Gαi/o, while GPR43 couples 
to Gαi/o and Gαq[199, 206] (Figure 1.3).  
Studies have demonstrated butyrate’s ability to signal through the nuclear receptor 
PPARγ in colonic enterocytes  Alex et al. [207] showed that butyrate acts as an agonist for 
PPARγ in human colonic enterocytes and that butyrate’s signaling through this pathway 
promotes angiopoietin-like 4 production, which plays a role in the regulation of systemic 
triglyceride levels. More recently, a study by Byndloss et al. [208] determined that loss of 
butyrate signaling though PPARγ shifted the metabolism of colonic enterocytes toward β-
oxidation, which increased available oxygen at the epithelial barrier, and drove increased 
expression of  Nos2 and thus increased luminal nitrate concentrations. They determined that 
the increase in oxygen and nitrate promoted the dysbiotic expansion of potentially 
pathogenic Escherichia and Salmonella. Thus, signaling through PPARγ likely represents an 
important pathway by which the presence of butyrate regulates host responses and the 
mucosal microbiome (Figure 1.3).  
Butyrate and Immune Cell Interactions 
Due to the observed alterations in BPB frequency and butyrate stool concentrations 
in both animal models of intestinal inflammation and human disease, the impact of butyrate 
on immune responses has been widely studied. Butyrate is an essential energy source for 
epithelial cells and a modulator of epithelial cell function. In the colon, where butyrate exists 
at higher concentrations[166, 167], butyrate alters colon epithelial cell (colonocyte) function 
and provides for roughly 70-90% of colonocyte energy demands by providing two acetyl-
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CoA molecules for the TCA cycle[171, 174, 192, 205, 209]. Butyrate also stabilizes HIF1α, 
which promotes an anaerobic environment at the colonocyte lumen interface[172], as well 
as decreases in the production of Nitric Oxide through agonism of PPARγ[208]. Butyrate 
has also been shown to alter the immunological responses of colonocytes through the 
upregulation of IL-10R[173], tight junction molecules such as Claudin-1 and downregulation 
of Cluadin-2[173, 209], and the production cytokines such as IL-18[204, 210].   
 The impact of butyrate on the adaptive and innate immune system has been studied 
widely in mice and human peripheral and immortalized leukocytes. Several studies have 
examined the effects of exogenous butyrate on in vitro T cell activation and proliferation.  
Cumulatively, these studies demonstrated that butyrate decreased CD4 and CD8 T cell 
cytokine production (IL-17 and IFNγ)[190, 211], activation[190-192], and proliferation[190-
192, 212-214] in response to exogenous stimuli. The mechanisms that drove these 
observations were primarily apoptosis[190, 192, 212-214] and HDACi[192]. Investigations 
into butyrate’s impact on CD4 T cell differentiation highlighted the critical role of butyrate in T 
regulatory cell function and differentiation. These studies demonstrated that butyrate 
increased the frequency of FoxP3+ CD4 T cells through either GPR43[215] signaling or an 
increase in Foxp3 gene expression through HDACi[194, 195, 216]. Also, butyrate has been 
shown to promote the differentiation of Th1 and Th17 cells. These studies demonstrated 
that depending on cytokine milieu, butyrate along with pro-Th1 cytokines (IL-12 and IFNγ) 
drove increased frequencies of Tbet expressing Th1 cells[188, 196]. Similarly, butyrate 
along with pro-Th17 cytokines (IL-6 and IL-1β) drove increased expression of Rorc 
expressing Th17 cells[188, 197].  In addition, both the concentration of butyrate and the 
differentiation state of CD4 T cells have been shown to alter the impact of butyrate on CD4 
T cells. Kesphol et al. [196] demonstrated that lower concentrations of butyrate (0.25 mM) 
increased the differentiation of Th regulatory cells, while higher concentrations of butyrate (1 
mM) increased the frequencies of Th1 cells. Butyrate has also been shown to increase IFNγ 
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and granzyme B expression in CD8 T cells [217]. Furthermore, a recent study determined 
that the addition of butyrate to differentiating CD8 and Th1 cells increased their production 
of IL-10, which helped decrease disease severity in a mouse model of colitis [188].  
Collectively, these observations demonstrate the effect butyrate on T cell function and 
development is varied and depends on the concentration of butyrate and state of 
differentiation of the T cell. 
 Butyrate has also been demonstrated to alter B cell function and antibody 
production. Through HDAC inhibition, butyrate has been shown to alter the differentiation of 
B cells and the production of immunoglobulin from B cells [218, 219]. Furthermore, when 
fiber levels were altered in the mouse colon, there were changes in stool IgA and IgG levels. 
These changes were determined to likely be mediated by epigenetic modifications of 
miRNAs silencing Aicda and Prdm1 mRNAs mediated by butyrate driven HDAC 
inhibition[218]. Therefore, SCFAs can alter B cell development, B cell responses, and 
antibody production.  
 Innate immune cells, which respond to microbial antigens and express TLR 
receptors, have been demonstrated to be impacted by exposure to butyrate. Neutrophils are 
an essential first line of defense against invading microbes, and the abundance and 
activation of these cells are also tied to tissue inflammation as seen in the mucosa of 
PLWH[126]. Butyrate decreased the production of reactive oxygen species and 
phagocytosis of C albicans in a study of rat intraperitoneal neutrophils. These effects were 
limited to butyrate as acetate and propionate did not have the same impact [220].  
Furthermore, it has been demonstrated that butyrate increased human neutrophil apoptosis 
after activation with the TLR4 ligand LPS[181]. Butyrate has also been shown to regulate 
antigen presenting cell  (macrophage and dendritic cell (DCs)) function and differentiation. 
Butyrate impacts DC differentiation through the upregulation of CD1a as well as the 
imprinting of CD103 and α4β7 expression in differentiating dendritic cells[221].  In 
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differentiated macrophages butyrate, through HDACi, decreased the specific cytokine (IL-6 
and IL-12) and functional (nitric oxide production) responses to TLR4 ligation and thus 
dampened responses to microbes[193]. Moreover, butyrate and propionate inhibited CD8 T 
cell activation by suppressing APC IL-12 production[222]. In cultured macrophages, butyrate 
depending on the differentiation media has been shown to promote the differentiation of the 
more homeostatic M2 macrophage populations[223] or a more anti-microbial subset 
characterized by the production of anti-microbial peptides S100A8/A9/A12[189]. While, there 
is evidence that butyrate programs DCs to drive the differentiation of T regulatory cells 
through both GPR109a signaling and HDACi[224] others have highlighted a deleterious role 
where butyrate administration to activated DCs drove the production of more IL-23 and oral 
butyrate administration during a murine model of colitis (DSS colitis) worsened symptoms 
potentially through DC production of IL-23 and Th17 activity[225].  
Finally, butyrate’s ability to regulate innate lymphoid cells (ILCs) has also been 
investigated in vivo. Butyrate has been demonstrated to decrease the murine ILC3s in the 
terminal ileum which resulted in a reduction in the frequency of T regulatory cells and 
increased antigen-specific effector T cells[226]. Furthermore, a murine model of airway 
hyperresponsiveness demonstrated that butyrate inhibited IL-13 and IL-5 production by 
ILC2s, which would likely protect against airway hyperresponsiveness[227].  Collectively, 
these studies demonstrated that butyrate is a potent mediator of innate immunity and that 
differentiation state, cytokine microenvironment and disease state all impact the effect of 









Figure 1.3. SCFA Signaling Pathways in Cells. The three primary SCFAs (butyrate, 
acetate, and propionate) alter target cell function through three primary pathways. They can 
act as HDACi to change cell function by inhibiting HDAC proteins. The can also signal 
through surface receptors GPR41 and GPR43, which have an affinity for all three SCFA and 
GPR109a which has an affinity for butyrate and niacin. Butyrate can also act as a PPARγ 






Project Rationale: Alterations in Colonic Mucosal Butyrate Producing Bacteria During 
Chronic HIV-1 Infection1 
Several studies of the gut microbiome of PLWH have demonstrated an HIV-1 
associated dysbiosis that is in part characterized by a lower relative abundance of taxa that 
contain BPB species. A study by Dillon, Kibbie et al. [229], demonstrated that the relative 
abundance of the summed total BPB species in the colonic mucosa was lower in PLWH.  
On the species level, Roseburia intestinalis was lower in PLWH and the relative abundance 
of this bacteria negatively associated with several markers of systemic inflammation, 
viremia, and microbial translocation. Furthermore, when the ratio of a known HIV-1 
associated enteric commensal bacteria (pathobiont) Prevotella stercorea to R. intestinalis 
was examined, there were strong positive associations with mucosal T cell activation and 
inflammation along with markers of microbial translocation(Figure 1.4). These observations 
suggest that there is a loss of colonic mucosal BPB species in PLWH, that occurs in 
conjunction with an increased abundance of pathobiont commensal bacteria in some 
individuals, and this promotes unregulated inflammatory responses in the mucosa and 
periphery as well as microbial translocation and HIV-1 replication. 
Scope of Thesis 
The infection and loss of Th cells in the gut mucosa and alterations in the GI tract 
microbiome are hallmarks of HIV-1 infection. The lower relative abundance of regulatory 
bacteria that contain BPB has been noted in HIV-1 infection as well as other inflammatory 
disorders of the gut mucosa. Therefore, it is of critical importance to understand how a loss 
of mucosal BPB species and thus likely decreased concentrations of mucosal butyrate, 
influence the function of gut CD4 T cells in the setting of inflammation and HIV-1 infection. 
                                                          
1 Portions of this section and figure have been previously published and is used with permission. Copyright © 
2018. AIDS, DOI: 10.1097/QAD.0000000000001366. 
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The focus of this thesis was two-part. First, I sought to understand the impact of 
butyrate on enteric HIV-1 associated commensal bacteria driven LP CD4 T cell activation 
and HIV-1BAL infection using a lamina propria mononuclear cells (LPMC) model of microbial 
translocation and acute HIV-1 infection. Next, I sought to understand how butyrate affects T 
cell receptor-mediated activation and HIV-1CH40 infection of LP CD4 T cells over a wider 
physiologic concentration range and carry out more extensive studies to determine the 
mechanism(s) by which butyrate is achieving this. For the first part of the thesis, I 
hypothesized that butyrate would decrease enteric bacteria-driven LP T cell activation, 
cytokine production, and HIV-1 infection. For the second part of the thesis, I hypothesized 
that exposure of LPMC or purified LP CD4 T cells to high physiologic concentrations of 
butyrate would dampen LP CD4 T cell activation, cytokine production, Th subset 
proliferation, and HIV-1 infection through its known activity as an HDACi.  
When I modeled the impact of butyrate on pathobiont-driven gut LP T cell activation 
and HIV-1 infection, there were significant decreases in both LP CD4 and CD8 T cell 
activation as determined by the co-expression of HLA-DR and CD38 as well as by IL-17 and 
IFNγ production at 2 mM butyrate. Furthermore, butyrate at this concentration significantly 
decreased the productive infection of LP CD4 T cells. The addition of butyrate at the lower 
concentration resulted in non-significant decreases in pathobiont driven T cell activation, 
cytokine production, and productive HIV-1 infection. Following up on these observations, I 
next determined that butyrate differentially affected T cell receptor-mediated LP CD4 T cell 
activation, proliferation, and HIV-1 infection depending on concentration. Specifically, at 
higher concentrations ≥0.25 mM, I noted that butyrate directly and likely via HDACi 
decreased LP CD4 T cell activation ( frequency of CD25+ and HLA-DR and CD38 co-
expressing cells), proliferation and productive HIV-1 infection. Conversely, at lower 
physiologic concentrations of butyrate ≤0.125mM, there was a limited decrease in LP CD4 T 
cell activation but an increase in productive HIV-1 infection which was likely mediated via 
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increased CCR5 expression and viral entry or reverse transcription. These effects at lower 
concentrations were noted only in the presence of other LPMC and not directly on the LP 
CD4 T cell populations. Collectively, the data presented in this thesis contribute to our 
understanding of the functional impact of alterations in BPB populations and likely mucosal 
tissue butyrate concentrations on LP CD4 T cell activation state and infection during HIV-1 
infection. Furthermore, these observations provide insight into possible butyrate centric 
interventions for the treatment of HIV-1 mucosal pathogenesis and the sequela of mucosal 















Figure 1.4.  Communities of Butyrate-producing Bacteria (BPB) are Reduced in the 
Colon Mucosa of Untreated HIV-1 Infected Study Participants.  Relative abundances 
(RA) of the major colonic butyrate-producing species were evaluated in 16S rRNA sequence 
datasets derived from the stool and colonic biopsies of 14 HIV-1 uninfected control (n=14) 
and untreated, chronic HIV-1 infected (n=17-18) study participants.  (A) Summed RA was 
determined in the stool, and colonic mucosa of HIV-1 uninfected (HIV-; n=14) (open circles) 
and untreated, chronic HIV-1 infected (HIV+; Stool n=18; colonic mucosa: n=17) (filled 
squares) study participants.  (B) RA of Roseburia intestinalis in the colonic mucosa of HIV-1 
uninfected (HIV-; n=14) (open circles) and untreated, chronic HIV-1 infected (HIV+; n=17) 
(filled squares) study participants.  (C) The ratio of RA of P. stercorea to R. intestinalis (P. 
stercorea: R. intestinalis) in colonic mucosa of HIV-1 uninfected (HIV-; n=14) (open circles) 
and untreated, chronic HIV-1 infected (HIV+; n=14) (filled squares) study participants.  RA of 
R. intestinalis was undetectable in 3 HIV-1 infected individuals. Therefore, a ratio was not 
calculated for these study participants (n=14).  (D) Correlations between P. stercorea: R. 
intestinalis and the number of activated (CD38+HLA-DR+) colon CD4 and CD8 T cells and 
activated colon CD1c+ mDC (CD40 expression levels) in HIV-1 infected study participants 
(n=14 for colon T cell activation; n=11 for colon CD1c+ mDC activation).  Lines represent 
median values (A-C).  Statistical analysis was performed using the Wilcoxon matched-pairs 
signed rank test to determine differences in matched groups (A), the Mann-Whitney test to 
determine differences between unmatched groups (A-C) and Spearman test to determine 





MATERIALS AND METHODS 
 
Human intestinal LPMC Isolation 
Human jejunal tissue that was deemed macroscopically normal was obtained from 
patients undergoing elective abdominal surgery and considered to be discarded tissue. 
Tissue samples from individuals with a clinical history of recent chemotherapy (less than 
eight weeks), hematologic malignancy, radiation, HIV-1 infection, immune-suppressing drug 
use or inflammatory bowel conditions were excluded from this study. Patients granted 
release of tissue to allow unrestricted use in research and all samples were de-identified 
with only age, sex, the reason for surgery and surgery-related treatment status information 
available. The use of these samples for research purposes was reviewed by the Colorado 
Multiple Institutional Review Board (COMIRB) at the University of Colorado Anschutz 
Medical Campus and was granted exempt research status. Tissue samples were processed 
as follows, jejunal tissue was first dissected, and the mucosa isolated mechanically. This 
was then followed by incubations with dithiothreitol (DTT) to remove mucus, 
ethylenediaminetetraacetic acid (EDTA) to remove the epithelial layer and lastly digestion 
with collagenase to isolate LPMC. LPMC were cryopreserved and stored in liquid nitrogen. 
PBMC Isolation 
PBMC were isolated from healthy whole blood donors (N=6) who voluntarily gave 
written informed consent. Whole blood collection was approved by COMIRB, University of 
Colorado, Anschutz Medical Campus. Blood was drawn in Vacutainer tubes containing 
sodium heparin. PBMC were isolated using Ficoll density gradient centrifugation and 





Growth of Bacteria Stocks 
Prevotella stercorea (DSM#18206, DSMZ, Braunschweig, Germany) was cultured at 
37 °C under anaerobic conditions using BD GasPak EZ Anaerobe Pouch Systems (BD 
Diagnostics, Franklin Lakes, NJ, USA) according to manufacturer’s protocols. P. stercorea 
was grown in liquid chopped meat broth (Hardy Diagnostics)  which was supplemented with 
1% Vitamin Supplements (ATCC), 0.05% Tween 80, 1% Trace Minerals (ATCC), 8.1 mM 
propionic acid, 29.7 mM acetic acid and 4.4 mM butyric acid (Sigma-Aldrich) for 5–7 days. 
P. stercorea was enumerated by flow cytometry using BD Liquid Counting Beads (BD) and 
stored long-term at −80 °C in 10% glycerol. Cells were subsequently suspended in DPBS for 
working stocks and stored at −80 °C in single-use aliquots. 
Preparation of CCR5-tropic CH40 Transmitted Founder Stocks and HIV-1Bal Stocks  
HIV-1Bal (AIDS Research and Reference Program #510) and mock-infected 
supernatant stocks were generated and frozen in single-use aliquots stored at −80°C as 
previously described[156, 230]. The Beatrice Hahn laboratory generated transmitted founder 
HIV-1 infectious molecular clone CH40. Plasmids containing CH40 were re-transformed and 
amplified in Stbl3 cells (Invitrogen) and purified using Qiagen maxi kit. The CH40 maxi-preps 
were verified by 13 HIV-specific primers to cover the entire genome. 40 μg of transmitted 
founder plasmids were used to transfect 293-T cells by CaCl2 transfection method. Virus-
containing and uninfected supernatants were collected at 48 hours, concentrated by 
ultracentrifugation at 141,000 RPM over a 20% sucrose cushion to generate both viral and 
mock stocks. Viral stock concentrations were determined by an HIV-1 Gag p24 ELISA kit 
(ABI). Frozen one-time use aliquots of virus and mock were frozen at -80°C for future use. 
LPMC and PBMC Culture Model.  
LPMC and PBMC were counted and plated at 1x106 LPMC/mL in 48 well culture 
plates using complete culture media (RPMI + 10% human AB serum + 1% 
penicillin/streptomycin/glutamine + 500µg/ml Zosyn (piperacillin/tazobactam) at 37˚C, 5% 
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CO2 and 95% humidity from 24 hrs. - Four days. T cell activating beads (anti-
CD3/CD2/CD28; Miltenyi) were added to culture conditions in a 1:25 (bead: LPMC) ratio and 
Prevotella stercorea 2.5:1 ( bacteria: LPMC). For assays using purified cells, LP CD4 T cells 
were isolated using the EasySep immunomagnetic negative selection kit (Stemcell 
Technologies) according to the manufacturer’s protocol.  To control for variance in cell 
responses due to the isolation process, total LPMC were also incubated with the separation 
buffer in place of the CD4 T cell Isolation Antibody Cocktail and all subsequent steps in the 
protocol were the same.  On average LP CD4 T cells were enriched to 93% of viable 
leucocytes (n=6).   
SCFA Assay Conditions 
For all conditions exposed to SCFA, butyric acid, glacial acetic acid, and propionic 
acid were diluted in culture media to working stocks (10-20 mM; 7.5pH) and then serially 
diluted at the time of assay set up (SCFA concentrations, acetate: 0.25-10mM, propionate 
0.25-2mM, butyrate 0.0625-0.5mM). Unless otherwise noted, LPMC and PBMC were 
cultured with SCFAs added concurrently with TCR activating beads or Prevotella stercorea. 
For studies examining the impact of butyrate pre-treatment on LP CD4 cell proliferation, 
LPMC were plated and exposed to butyrate (butyric acid) for 0, 2, 6 and 8 hours before 
exposure to TCR activating beads. The conditions examining the impact of butyrate addition 
after TCR activating bead exposure, butyrate was at 0, 6, 18 and 36 hours after TCR bead 
exposure.  
Small Molecule PPARγ, HATi and HDACi Assays 
LPMC were set up as previously mentioned in the sections describing LP CD4 T cell 
activation and LP CD4 T cell proliferation. Rosiglitazone, T 0070907, C646, trichostatin A, 
apicidin, MGCD, and ITF2357 were diluted to working stocks of 1000nM in culture media 
and serially diluted at the time of assay set up. Apicidin, MGCD, and ITF2357 were kindly 
provided by Timothy McKinsey (University of Colorado Anschutz Medical Campus). The 
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impact of HDACi on TCR mediated LP CD4 T cell activation, and proliferation was 
determined by the examination of changes in LP CD4 T cell expression of activation 
markers (HLA-DR+CD38+ and CD25+) and proliferation (CFSEdim) while studies with HATi 
and PPARγ focused assays only used proliferation as a readout.   
Quantification of Secreted Cytokine Production 
Levels of IL-17, IL-2 and IFN in culture supernatants were quantified using Ready-
Set-Go ELISA kits (ThermoFisher). Assays were carried out according to the manufacturer’s 
protocols.  
FLOW Acquisition and Analysis   
All flow cytometry data were acquired on an LSRII flow cytometer (BD Biosciences) 
and analyzed using FlowJo version 10. The Cytometer Setup and Tracking feature using BD 
FACSDIVA software (V6.1) and routine quality control were performed daily as previously 
described[231]. 
Measurement of LP CD4 T Cell Activation 
After four days of culture with or without butyrate and activating stimuli, culture 
conditions were harvested, surfaced stained and analyzed by multicolor flow cytometry. 
Detailed gating strategies are outlined in supplemental figures (Figure 2.1, Table 2.1)).  To 
enumerate populations of interest, viable LP CD4 T cells were identified (Zombie dye 
negative(Biolegend) within a total lymphocyte gate based on forward and side scatter 
properties cells and doublets were excluded using forward-scatter-height versus forward-
scatter-width properties.  CD4 T cells were identified as CD3+(PerCpCy5.5, TONBO, Clone: 
OKT3), CD4+ (V450, TONBO, Clone: RPA-T4) and CD8- (APC, TONBO, Clone: RPA-T8), 
cells.  LP CD4 T cell activation was determined by enumerating the percentage of CD4 T 
cells that co-expressed CD38 (AF700, eBiosciences, Clone: HIT2) and HLA-DR (APC-Cy7, 
BioLegend, Clone: L243) as well as the percentage of cells that expressed CD25 (PE, BD, 
Clone: M-A251). In studies with P stercorea, activation was only enumerated by CD38 and 
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HLA-DR. For final reported values, isotype and FMO control values were subtracted and 
data displayed as the net value. 
Measurement of LP CD4 T Cell Proliferation 
 In experiments enumerating proliferation of LP T cells, LPMC or purified LP CD4 T 
cells were labeled with 1M CellTrace CFSE (Invitrogen) per manufacturer’s instructions 
before setting up culture conditions.  CFSE-labeled cells were exposed to various 
concentrations of SCFA and HDACi as mentioned above.  LPMCs were cultured with or 
without TCR activating beads for four days at 37˚C, 5% CO2 and 95% humidity.  Cultures 
were collected, and CD4 T cell proliferation (CFSEdim) was determined by multi-color flow 
cytometry. Proliferating CD4 T cells were enumerated by the percentage of CFSEdim CD4 T 
cells with the CFSE gate established on the unstimulated control condition(Figure 2.1, 
Table 2.1).   
Measurement of LP CD4 T Regulatory Cell Frequency 
LPMC were cultured for either 24 hrs or four days in the presence or absence of 
butyrate (0.25 and 0.5mM). At baseline and after culture cells, were stained using FOXP3 
Fix/Perm Buffer Set (Biolegend) with the following antibodies: CD45+(PerCpCy5.5, 
eBiosciences, Clone: 2d1),  CD3+(PE-Dazzle, Biolegend, Clone: UCHT1), CD4+ (APC, 
TONBO, Clone: RPA-T4) and CD8- (PE-Cy7, TONBO, Clone: RPA-T8), CD25 (PE, BD, 
Clone: M-A251) and FOXP3 (AF488, eBiosciences, Clone: PCH101) and rat IgG2a 
(eBiosciences) (Table 2.1). 
LP and PB CD4 T Helper Cell Proliferation  
LPMC or PBMC were labeled with CFSE initially and after 4 days of culture, cells 
were stimulated with a final concentration of phorbol myristate acetate (25ng/ml) and 
Ionomycin (5ng/ml) in the presence of 1 μg/ml Brefeldin A (Golgi Plug) for 4 h at 37°C in 5% 
CO2. LPMC were collected and measurement of proliferated Th cells determined using 
multi-color flow cytometry.  LP CD4 T cells were identified using the following antibodies: 
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CD3 (PerCpCy5.5, TONBO, Clone: OKT3), CD4 (APC, Biolegend, Clone: RPA-T4) and CD8 
(PE-Dazzle, TONBO, Clone: RPA-T8) and viability dye. Cells were fixed using Medium A 
(Invitrogen, Carlsbad, CA) and permeabilized using Medium B (Invitrogen). Intracellular 
cytokine staining was then used to characterize Th subsets. The following antibodies were 
used IL-17 (V450, eBiosciences, CLONE: N49-653), IFN (AF700 BD, clone: B27), and IL-
22 (PE-Cy7, Biolegend, clone:22URTI). Matched isotypes were used to determine positive 
staining and CFSE labeling to assess proliferation. Th subsets were characterized as 
follows: Th17 were any LP CD4 T cell producing IL-17, Th1 were LP CD4 T cells that 
produced IFN and could also produce IL-22, Th22 were LP CD4 T cells that only produced 
IL-22, and lastly there was a subset characterized the absence of the production of these 
three cytokines (Figure 2.2, Table 2.1) 
Studies to Understand Butyrate’s Mechanism of Action 
Quantification of Histone H3 Acetylation 
To determine Histone H3 lysine 9 (H3K9) acetylation levels by flow cytometry, LPMC 
were cultured with or without butyrate (0.5mM) and TCR activating beads and harvested 
after 24 hours of culture. LP CD4 T cells were identified using the following antibodies: CD3 
(PerCpCy5.5, TONBO, Clone: OKT3), CD4 (APC, Biolegend, Clone: RPA-T4) and CD8 (PE-
Dazzle, TONBO, Clone: RPA-T8) and viability dye. Cells were next fixed using Medium A 
and permeabilized using Medium B (Invitrogen) and stained according to the protocol 
outlined in [232] for acH3K9(Millipore) and a Donkey anti-rabbit IgG secondary antibody 
(AF488, Biolegend) to determine acH3 expression.  Expression levels of acH3 were 
determined by LP CD4 T cell mean fluorescence intensity (MFI) with secondary only values 






Figure 2.1. Flow Gating Scheme for Stimulated LP CD4 T cell Activation and 
Proliferation Studies. 
LPMC were stimulated with TCR stimulating beads for four days. Cells were harvested and 
stained with fluorescent antibodies. In short, live cells were first gated using a viability 
exclusion dye, FSC-A and SSC-A next determined size and granularity. FSC-W and FSC-H 
then excluded doublets. Next CD3+ cells were gated, followed by CD4+CD8- cells. 
Activation (CD25, HLA-DR and CD38) were gated using FMO (CD25, HLA-DR) and Isotype 
(CD38) controls. Proliferation (CFSEdim) was gated based on corresponding conditions 





Supplemental Figure 2.2. Flow Gating Scheme for the Identification of T helper 
Subsets 
Flow gating scheme for the identification of T helper subsets. In short,  LPMC were activated 
with TCR stimulating beads for four days after which time T helper subsets were determined 
by cytokine expression after PMA/ionomycin stimulation + Golgi plug for the final four hours 
of culture. Proliferation (CFSEdim) was determined for the following populations: Th17 (all 
IL-17+ LP CD4 T cells), Th1(LP CD4 T cells that express IFNγ but not IL-17 but can express 
IL-22), Th22 (LP CD4 T cells that only express IL-22) and LP CD4 T cells that do not 













Figure 2.3 Butyrate Increases LP CD4 T Cell  Histone Acetylation Levels (acH3K9). 
Example flow plots for LPMC treated with butyrate 0.5mM or 0mM control in the setting or 
absence of TCR stimulation. LP CD4 T cells were gated, and acH3K9 MFI values 
determined acH3K9 expression after 24 hours. Secondary only staining was used for 














H3K9 protein levels were also assessed using western blot in the absence of 
stimulation. Purified LP CD4 T cells were cultured in the presence of butyrate at 0.125 and 
0.5mM for 24 hours. Protein was extracted using Tris lysis buffer in the presence of a 
protease inhibitor (Roche). Total protein was quantified for normalization using a Pierce 
BCA protein assay kit. The following antibodies were used: anti–-actin (conc: 1:50,000, 
Abcam) and anti-acH3K9 (conc: 1:10,000, Rabbit Polyclonal, Millipore).  Peroxidase goat 
anti-rabbit IgG and peroxidase goat anti-mouse IgG were used according to manufactures 
recommendations. Pierce ECL substrate (Thermo Fisher Scientific) and Criterion XT Bis-Tris 
Gels (Bio-Rad) were also used, and expression levels were quantified using ImageJ 
software. 
LP CD4 T cell GPR Expression 
GPR43 and GPR109a expression were determined at baseline and after four days 
culture on LP CD4 T cells. LP CD4 T cells were cultured in the presence or absence of TCR 
activation and butyrate (0.5mM). LP CD4 T cell flow staining was determined by CD3+ 
(PerCpCy5.5, TONBO, Clone: OKT3), CD4+ (TONBO, Clone: RPA-T4) and CD8- (PE-
Dazzle, TONBO, Clone: RPA-T8) and viability dye. Cells were also stained for GPR109a 
(PE, R&D, clone: 245106) and GPR43 (AF647, Bioss Antibodies, clone: polyclonal) 
expression. Isotypes were used to determine positive staining (Table 2.1).  
Flow-cytometry Based Measurement of Productive HIV-1 Infection  
Total LPMCs and purified LP CD4 T cells were spinoculated with CH40 transmitted 
founder virus (100ng p24 per 1x106 LPMCs) in a final concentration of 2.5x106 LPMCs/ml. 
LPMCs were mock infected using culture supernatants from 293T cell cultures and 
conditioned in the same manner as the HIV-1 infected cells. Spinoculation was carried as 
previously detailed[156, 231]. LPMCs were cultured with butyrate and stimulation as 
described earlier. After 4 days of culture, productive infection was measured by the 
frequency of total CD3+( PE-Dazzle, Biolegend, clone: UCHT1), CD8- (APC, Tonbo, clone: 
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RPA-T8) cells and Th subsets (enumerated after  treatment with phorbol myristate acetate 
and Ionomycin in the presence of 1 μg/ml Brefeldin A), expressing the viral nucleocapsid 
protein p24 (PE, Beckman Coulter, clone: KC57). CD3+CD8- cells were used to determine 
the productive infection of total LP CD4 T cells since it is known that CD4 is down-regulated 
during HIV-1 infection[233]. p24 background staining in mock conditions was removed to 
determine true p24 positive populations in the HIV-1 infected conditions.  
HIV-1 Infection Related Assays 
TZM-bl Assay 
Infectious titers present in culture supernatants were determined in TZM-bl reporter 
cells after 4 days of culture.  TZM-bl cells were plated in 96-well plate white polystyrene 
microplates in culture media (DMEM+ 10% FBS + 1% PSG) with dextran sulfate (100 
ng/ml). Culture supernatants from infection assays were then added to individual wells and 
incubated for 48 hours at 37˚C, 5% CO2 and 95% humidity. Brite lite luciferase reagent 
(Perkin Elmer) was added to each well. A VictorX5 plate reader (Perkin Elmer) was then 
used to determine Relative Light Units (RLU) of luminescence.  
HIV-1 Co-receptor Expression Analysis   
LPMC and purified LP CD4 T cells were cultured as previously described. After four 
days of culture, cells were stained for extracellular expression of CCR5 (PE-Cy7, BD, clone: 
2D7/CCR5) and CD4 (V450, Tonbo, clone: RPA-TA4). LP CD4 T cells were gated as 
previously mentioned, and CCR5 and CD4 MFI values of each were reported with isotype 
values removed(Figure 2.5, Table 2.1). 
HIV-1 RU-5 Quantification  
To quantify HIV-1 RU-5 DNA, LPMC were spinoculated, activated and exposed to 
butyrate as outlined above and exposed to Raltegravir (NIH AIDS Reagent Program) at 1M 
to prevent integration of HIV-1 into the host genome. After 24 hours of culture, LP CD4 T 
cells were sorted using Astrios Cell Sorter (University of Colorado Cancer Center), and DNA 
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was isolated using DNeasy mini kit (Qiagen). Primer and probe (TaqMan) combinations 
were used to quantify HIV-1 RU-5 and RNaseP (Thermofisher). Each reaction contained 10 
pmol of primer and probe, and Gene Expression Mastermix (Life Technologies) was used 
according to manufacturer’s instructions. The following thermocycling conditions were used: 
50°C 2 min and 95°C 10 min, then 40 cycles of 95°C 15s and specific annealing 
temperatures for each target were used (RU-5: 60°C 45 s; RNaseP: 60°C 60). qPCR 
reactions were run on the Biorad CFX96 rtPCR machine. Primer sequences: RU-5: F-
CTGGCTAGCTAGGGAACCCACTG,R-GAGTCCTGCGTCGAGAGAGCTCC,P-
TCAAGTCCCTGTTCGGGCGCCACTG. RNase P cell number quantification (Thermofisher) 
was used according to manufacturer’s recommendations.  
HIV-1 Gag Quantification 
To quantify HIV-1 gag RNA, LPMC were spinoculated, activated and exposed to 
butyrate as outlined above in the presence of Amprenavir (NIH AIDS Reagent Program 
Bethesda, Maryland) at 1 µM to prevent multiple rounds of infection. After 48 hours of 
culture LP CD4 T cells were isolated by negative selection as outlined above (purity on 
average 88%) and RNA was isolated using RNeasy minikits (Qiagen). Primer and probe 
(Taqman) combinations were used to quantify HIV-1 gag and GAPDH. Each reaction 
contained 10 pmol of primer and probe, and Gene Expression Mastermix (Life 
Technologies, Carlsbad, CA) was used according to manufacturer’s instructions. The 
following thermocycling conditions were used: 50°C 2 min and 95°C 10 min, then 40 cycles 
of 95°C 15s and specific annealing temperatures for each target were used (GAPDH: 
64.5°C 45 s; gag: 65.5°C 45 s). qPCR reactions were run on the Biorad CFX96 rtPCR 
machine. Primer sequences: GAPDH: F CCCATGTTCGTCATGGGTGT   R-
TGGTCATGAGTCCTTCCACGAT, P-CTGCACCACCAACTGCTTAGCACCC; gag: F- 




Statistical Analysis  
Statistical analysis and graphing were performed using GraphPad Prism Version 6 
for Windows 10. Parametric two-tailed tests were performed. Mann-Whitney tests were used 
to compare unmatched groups, and correlations analyzed using Spearman's test. 
Differences between groups of matched paired data were performed using the Wilcoxon's 
matched-pairs signed-rank test, and multiple groups of matched paired comparisons were 
performed using the Friedman test with multiple Dunn comparisons. Significance was 
determined at P< 0.05. Inhibitory Capacity of 50% was determined using raw data values 
and log-transformed SCFA or apicidin concentrations using the following function 
log(inhibitor) vs. response with a variable slope (four parameters) with interpolation of 















Figure 2.4. Flow Gating Scheme for the Identification of Productive Infection of LP 
CD4 T Cells 
Flow gating scheme for the identification of productively HIV-1 infected (p24+) LP CD4 T 
cells after four days of infection in the setting of TCR stimulation. LPMC were harvested and 
stained by multicolor flow cytometry. Cells were gated as follows: Viable, single cell 
lymphocytes were gated first by CD3. CD3 cells were then gated into CD8 negative 
population due to the down-regulation of CD4 by HIV-1 infection. These cells were then 


















Figure 2.5. Flow Gating Scheme for the Quantification of CCR5 Expression on LP CD4 
T Cells  
LPMC were cultured for four days in the setting of TCR stimulation and cells were then 
harvested, stained and examined by multi-color flow cytometry. Populations were gated as 
follows: Viable, single cell lymphocytes were gated first by CD3. CD3 cells were then gated 
into the CD4+ CD8- population. These cells were then gated by CCR5 expression with 
isotype stain acting as gating controls for CCR5. CD4 and CCR5 expression were 
determined by the MFI of CD4 and CCR5 in the CD4+ population with isotype MFI values 






























EXOGENOUS BUTYRATE DECREASED ENTERIC PATHOBIONT DRIVEN LP T CELL 
ACTIVATION AND HIV-1 INFECTION2 
 
Preface 
The data presented in this chapter is comprised of sections of a manuscript that I co-
first authored with Dr. Stephanie Dillon. The clinical data generated for my co-first author 
work is detailed in the introduction.  
Background 
Human immunodeficiency virus (HIV)-1 disease is associated with dramatic 
alterations in the gut-associated lymphoid tissue (GALT) that occur early in the course of 
infection and contribute to HIV-associated chronic immune activation and disease 
progression.  HIV-associated GI tract pathology is characterized by early and high-level HIV-
1 replication and a dramatic depletion of mucosal effector CD4 T cells [36, 40, 45] especially 
T helper (Th) 17 and Th22 cells [43, 44, 102, 114-116, 234] in GALT.  Concomitant with T 
cell depletion, increased frequencies of activated gut CD8 T cells [57, 235-237], alterations 
in innate immunity [57, 71, 126, 238-241],  generalized gut inflammation [242, 243] and 
significant epithelial barrier damage [126, 236, 244-246] occur.  The cumulative impact of 
these structural and immunological changes is an increase in translocation of commensal 
bacteria and bacterial products from the gut lumen into the lamina propria (LP) and 
ultimately into the systemic circulation, a process called microbial translocation (MT).  MT 
has been associated with systemic immune activation [100] and predicts disease 
progression in untreated HIV-1 infected individuals [107].  Its persistence during effective 
                                                          
2 The work presented in this chapter has been previously published along with data presented in the 
introduction and is used with permission. Copyright © 2018. AIDS, DOI: 10.1097/QAD.0000000000001366. 
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antiretroviral therapy (ART) predicts mortality and is associated with several co-morbidities 
and immune activation and inflammation [247, 248].   
 Intestinal bacterial communities (microbiome) and their metabolites are essential in 
shaping and maintaining gut immunity [249]. Recent studies by our group and others 
demonstrated dysbiotic fecal and intestinal mucosal microbiomes during both untreated and 
ART-treated HIV-1 infection [57, 103, 111, 146, 147, 149, 151, 153, 250-255].  Our lab 
previously demonstrated that the relative abundance (RA) of Gram-negative Proteobacteria 
and Prevotella spp. were increased whereas Firmicutes and Bacteroides spp. were reduced 
in the colonic mucosa of individuals with untreated HIV infection.  This dysbiotic profile was 
associated with MT and mucosal and systemic immune activation.  Recent work exploring 
the impact of sexual preference on HIV-1 associated gut microbiome dysbiosis determined 
that a Prevotella rich dysbiosis was associated with men who have sex with men (MSM) 
sexual preference rather than with HIV-1 infection status [160].  Although the increase in RA 
of Prevotella in our study could have been due in part to sexual preference, our finding that 
mucosal Prevotella spp RA correlated with colonic myeloid dendritic cell (mDC), and T cell 
activation [57, 103] provides a link between dominant mucosa-associated microbes and 
inflammation in the setting of MT.  We have also recently demonstrated that commensal 
bacteria of the Prevotella genus have direct pro-inflammatory potential by activating gut 
mDC and increasing HIV-1 replication and CD4 T cell death in an ex vivo human intestinal 
cell model [57, 256].  Therefore, although the increase in Prevotella observed in our study 
[57, 103], as well as in others [146, 149, 255] could potentially contribute to HIV-1 
associated gut pathology. 
Microbial metabolites, byproducts produced by intestinal bacteria, are also important 
in influencing immune responses [165].   In our previous study [103], we observed a 
decrease in RA of Firmicutes, a phylum which includes bacteria known to produce the short 
chain fatty acid (SCFA) butyrate [257].  Butyrate, a fermentation product of insoluble dietary 
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fiber, is one of three primary SCFAs produced in the colon [258], and decreases in 
abundances of butyrate-producing bacteria (BPB) occur in several inflammatory diseases of 
the GI tract such as Crohn’s disease, ulcerative colitis and colon cancer[259-261].   Butyrate 
has been reported to play essential roles in colonic T regulatory cell differentiation [195, 204] 
and in modulating both gut and blood antigen presenting cell (APC) and T cell activation 
[190, 193, 262, 263]. In addition, butyrate is an essential energy source for colonic epithelial 
cells that promotes epithelial barrier integrity [264-267]. However, despite the known 
immune-regulatory role of butyrate, little is known about its role in regulating mucosal 
inflammation in the setting of HIV-1 infection. 
In this chapter, I investigated the impact of exogenous butyrate on Prevotella 
stercorea driven T cell activation and HIV-1 infection using an ex vivo human intestinal cell 
model of MT and acute HIV-1 infection.    
Results 
Butyrate Reduces P. stercorea-driven Activation of LP T Cells in vitro 
The clinical study observations outlined in the introduction demonstrated that 
increasing abundances of Prevotella spp. in conjunction with decreasing abundance of R. 
intestinalis associated with increased colon T cell activation. This observation led me to 
hypothesize that a loss of butyrate may exacerbate P. stercorea driven intestinal T cell 
activation.   To address this, I used an ex vivo human LPMC model which allows us to mimic 
the effect of translocating bacteria (i.e., MT) on LP T cell function in the setting of HIV-1 
infection.  In these in vitro assays, butyrate at a high (2mM) and low (0.2mM) concentration 
were used which agree with published studies using butyrate[192, 193, 268].  
To determine if butyrate modulated the activation of LP CD8 and CD4 T cells in the 
absence of HIV-1 infection, Mock-infected LPMC were exposed to Prevotella stercorea and 





Figure 3.1  Butyrate decreases P. stercorea driven lamina propria CD4 and CD8 T cell 
activation and cytokine production in the absence of  HIV-1 infection in vitro.  Lamina 
propria mononuclear cells (LPMC) were spinoculated with mock-infected culture 
supernatants and cultured with or without P. stercorea and butyrate (0.2mM, 2mM) for four 
days and levels of T cell activation and cytokine production determined (n=9). Percentages 
of LP CD4 (A) and CD8 (B) T cells co-expressing CD38 and HLA-DR were assessed using 
multi-color flow cytometry.  FMO and isotype control values have been subtracted.  Levels of 
IFNγ (C) and IL-17A (D) in culture supernatants at day 4 were evaluated by ELISA.  P. 
stercorea-specific (Δ) values are shown as net values (P. stercorea/mock minus mock 
alone). Statistical significance was determined using the Wilcoxon matched pairs signed 
rank test and the Friedman’s test with comparisons to no butyrate controls. (**P<0.01, 
***P<0.001). Data displayed as box and whiskers are represented with the box extending 
from the 25th to 75th percentile with the median value represented as the central line in the 








Figure 3.2 Butyrate reduces P. stercorea-enhanced LP T cell activation and HIV-1 
productive infection   Lamina propria mononuclear cells (LPMC) were spinoculated with 
CCR5-tropic HIV-1Bal and cultured with or without P. stercorea and butyrate (0.2mM, 2mM) 
for 4 days and levels of T cell activation, cytokine production and productive HIV-1 infection 
determined (n=9). Percentages of LP CD4 (A) and CD8 (B) T cells co-expressing CD38 and 
HLA-DR were assessed using multi-color flow cytometry.  FMO and isotype control values 
have been subtracted.  Levels of IFNγ (C) and IL-17A (D) in culture supernatants at day 4 
were evaluated by ELISA. Percentages of p24-expressing LP CD4 T cells (E-F) were 
assessed using multi-color flow cytometry.  P. stercorea-specific (Δ) values are shown as net 
values (P. stercorea/HIV-1 minus HIV-1 alone). Statistical significance was determined using 
the Wilcoxon matched pairs signed rank test and the Friedman’s test with comparisons to no 
butyrate controls. (**P<0.01, ****P<0.0001). Data displayed as box and whiskers are 
represented with the box extending from the 25th to 75th percentile with the median value 





increased LP CD4 and CD8 T cell activation (co-expression of HLA-DR and CD38) and 
cytokine production (IFNγ and IL-17) (Figure 3.1). When exogenous butyrate was added to 
these cultures, butyrate at 2mM decreased LP T CD4 and CD8 T cell activation(Figure 3.1 
A-B) and cytokine production(Figure 3.1 C-D) with minimal effects seen at 0.2mM butyrate.  
Butyrate Reduces P. stercorea-driven Activation of HIV-1 Infected LP T Cells in vitro 
 In the absence of butyrate, the addition of P. stercorea to HIV-infected LPMC 
cultures significantly increased LP CD4 T cell activation levels to above those induced in 
with infection alone (Fig. 3.2A).  The addition of 2mM butyrate significantly decreased P. 
stercorea-associated LP CD4 T cell activation (Fig. 3.3A) to that at or below levels observed 
with HIV infection in the absence of bacteria, whereas 0.2mM butyrate had minimal effect on 
LP CD4 T cell activation.  Similar suppressive effects of higher doses of butyrate were 
observed on LP CD8+ T cell activation, which was also increased in the presence of P. 
stercorea (Fig. 3.2B).  
Butyrate Decreases LPMC Production of IFNγ and IL-17 in Response to P. stercorea  
Based on the observation that butyrate reduced P. stercorea-driven LP T cell 
activation, I next evaluated T helper cytokine production as a functional readout of LP CD4 T 
cell activation. The addition of P. stercorea to HIV-infected LPMC cultures led to higher 
production of IFNγ and IL-17 in culture supernatants (Fig. 3.2C and D) compared to HIV-
infected cultures alone. Butyrate inhibited both IFN-γ(Fig. 3.2C) and IL-17 (Fig. 3.2D) 
production in a dose-dependent manner, with complete suppression observed at the higher 
2mM dose 
Butyrate Inhibits P. stercorea Driven HIV-1 Infection in LP CD4+ T cells  
We have previously shown that P. stercorea enhances LP CD4 T cell infection levels 
in our LPMC model[156].  Therefore, I aimed to investigate the impact of butyrate on P. 
stercorea-driven LP T cell infection.  In agreement with this previous study, exposure of HIV-
1Bal-infected LPMC to P. stercorea in the absence of butyrate significantly increased the 
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percentage of p24+ LP CD4 T cells compared to HIV-1Bal infection alone (Fig. 3.2E).  
Addition of 2mM butyrate suppressed P. stercorea driven LP CD4 T cell infection to levels 
observed with virus infection alone, whereas 0.2mM butyrate had a minimal effect (Fig. 
3.2F).  Butyrate had no noticeable impact on HIV-1Bal infection levels detected in the 
absence of P. stercorea (Fig. 3.2F).  
Discussion 
Microbial translocation has been linked to mucosal and systemic inflammation and is 
predictive of disease progression and mortality in HIV-1 infected individuals [247, 248].  It is 
thus of critical importance to understand the mechanisms by which gut microbes influence 
immune function during HIV-1 infection. In this chapter, in vitro studies demonstrated that 
higher levels of butyrate inhibited pathobiont-driven LP T cell activation and HIV-1 infection 
of CD4 T cells, whereas lower levels of butyrate lacked this strong immunomodulatory 
effect.  Taken together, these in vitro observations suggest that a loss of colonic mucosal 
BPB, with a presumptive decrease in mucosal butyrate levels, in conjunction with an 
increased abundance of pro-inflammatory, pathobiont commensal bacteria promotes 
unregulated inflammatory responses and mucosal HIV-1 replication, which could further 
drive epithelial barrier damage and microbial translocation. 
Butyrate plays several critical roles in colonic epithelial (colonocyte) function 
including by acting as a metabolic energy source for colonocytes[264-267], by increasing 
tight junction-mediated barrier integrity [269] and by protecting colonocytes from cellular 
damage and stress [172, 270].  Further, it has been shown that by decreasing NF-κB 
activation in metabolically stressed colonic epithelial cell lines, butyrate subsequently 
prevented transcytosis of E. coli in an in vitro epithelial cell/bacteria co-culture model [265]. 
Although the causality of these findings cannot be inferred, they suggest that reduced levels 
of butyrate may be a contributing factor to HIV-1-associated epithelial barrier breakdown 
that leads to MT.   
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Butyrate impacts cellular responses via G-coupled Protein Receptor (GPR) signaling 
(GPR41, GPR43, and GPR109a) as well as through histone deacetylase inhibition (HDACi), 
[258, 271] with an increased dosage favoring HDACi activity [272].  Butyrate functions 
through these two pathways to decrease immune cell activation [204, 259], inhibit T cell 
proliferation [190, 273] and increase apoptosis of activated T cells [190, 192].  In this study, 
higher doses of butyrate were associated with the most significant inhibition of T cell 
activation and CD4 T cell infection.  Therefore, the butyrate-dependent decrease in the 
production of T cell cytokines following exposure to bacteria could be driven by inhibition of 
T cell activation/proliferation, increased the death of activated T cells or, most likely, a 
combination of both.  Further examination of butyrate’s GPR signaling and HDACi activity 
and the downstream effects on LP T cell activation/proliferation and cell death are 
warranted. Nevertheless, the data outlined in this chapter suggest that strategies to increase 
butyrate levels could potentially improve barrier integrity, reduce mucosal T cell activation, 
and decrease MT.  The extent to which the HIV-associated mucosal pathology is reversible 





BUTYRATE DIFFERENTIALLY IMPACTS LP CD4 T CELL ACTIVATION AND 
INFECTION IN VITRO IN A CONCENTRATION DEPENDENT MANNER3 
 
Background 
HIV-1 disease is characterized by a state of chronic immune activation that is 
associated with poor clinical outcomes and increased morbidity and mortality even in the 
presence of effective viral suppression with antiretroviral therapy[274, 275]. One of the 
primary mediators of HIV-1 associated immune activation is the profound breakdown in 
intestinal homeostasis that occurs early and throughout the disease. This is characterized 
by high levels of HIV-1 infection and CD4 T cell depletion in the intestinal mucosa[36, 37, 
40, 43], including the depletion of T helper (Th) 17 populations[37, 43] that support epithelial 
barrier integrity via IL-22 production and protection from pathogens[276]. In persons living 
with HIV-1 (PLWH), several studies have noted lower abundances of genera in the gut 
microbiome that contain known butyrate-producing bacteria such as Lachnospira [145, 146, 
148], Coprococcus [103, 145, 146], Roseburia [145, 146, 148, 154] and Faecalibacterium 
[145, 146] . The abundances of several of these bacterial genera inversely associated with 
markers of inflammation. For example, one study determined that the relative abundance of 
Faecalibacterium in the stool of PLWH who were on antiretroviral therapy (ART) negatively 
associated with serum sCD14 levels[146]. We previously demonstrated that untreated 
PLWH had a lower relative abundance of Roseburia intestinalis, a known BPB, than 
uninfected controls in colonic mucosal biopsies.  Furthermore, R. intestinalis was inversely 
associated with blood CD4 T cell activation, markers of microbial translocation, circulating 
inflammatory cytokines and viral load[229].  
                                                          
3 The data presented in this chapter are in preparation for submission. 
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Several studies have demonstrated that exogenous butyrate decreases activation of 
human peripheral blood (PB) and immortalized T cells as well as murine splenic T cells 
through alterations in the expression of proteins involved in activation, cell cycle regulation 
and cell death[190-192, 214]. In some studies, butyrate has also been shown to promote the 
differentiation of Th1 and Th17 cells from naïve human peripheral blood and murine splenic 
CD4 T cells [188, 196]. Furthermore, butyrate decreased Th17-associated transcription 
factor activity and Th17-related gene expression in differentiating human Th17 cells but 
increased their expression in fully differentiated human Th17 cells[197]. Also, murine studies 
have highlighted that butyrate signaling through GPR43, and its activity as a histone 
deacetylase inhibitor (HDACi) are essential drivers of T regulatory cell differentiation[188, 
194-196, 215]. Thus, the impact of butyrate on CD4 T cell function may be multifactorial 
depending on the type of T cells as well as their differentiation state. 
In contrast to PB CD4 T cells, gut mucosal CD4 T cells are primarily resident effector 
memory cells that display different phenotypic and functional characteristics[80-82]. Given 
their proximity and consistent exposure to higher concentrations of butyrate, these cells may 
be more primed to respond to butyrate compared to the CD4 T cell populations in the 
periphery. Thus, information about how PB T cells responded to butyrate may not directly 
translate to what occurs in the gut mucosa.  We previously demonstrated that the addition of 
high doses of exogenous butyrate decreased gut CD4 T cell activation by exposure to 
enteric bacteria and reduced levels of CD4 T cell HIV-1 infection in vitro [229];  however, the 
mechanisms by which butyrate modulated those responses have not presently been 
investigated.  In this chapter, I utilized an in vitro model to comprehensively evaluate the 
impact of a range of physiologically relevant concentrations of butyrate on T cell receptor 
(TCR) driven LP CD4 T cell activation and HIV-1 infection and to determine the mechanisms 
by which this occurs. I previously used this model to investigate the impact of butyrate on 
enteric pathobiont driven T cell activation. In the studies presented in this chapter, I used 
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TCR stimulation to study direct T cell activation. Comprehensively, these studies offer 
greater insight into how lower BPB and thus likely lower butyrate tissue concentrations may 
impact gut mucosal CD4 T cell function in the setting of HIV-1 infection in vivo. 
Results 
In vitro Exposure to Exogenous Butyrate Decreases TCR-mediated LP CD4 T Cell 
Activation and Proliferation Directly in a Concentration-dependent Manner. 
TCR stimulatory beads were used to directly stimulate LP CD 4 T cells, to mimic the 
process of antigen presentation that would occur during microbial translocation. To 
determine the ability of butyrate to modulate LP CD4 T cell activation and proliferation in the 
setting of TCR-mediated activation, total LPMC were stimulated with or without TCR-
stimulatory beads directed against CD3, CD2 and CD28, in the presence of a physiologic 
concentration range of butyrate (0.0625-0.5mM). The concentration range used was 
determined based on reported measured concentrations of butyrate in the gut lumen and 
portal circulation of human subjects [166, 167] and had limited impact on overall cell viability 
(Fig. 4.1). The ability of butyrate to modulate LP CD4 T cell proliferation as measured by 
CFSE dilution and T cell activation assessed by CD25 expression and HLA-DR and CD38 
co-expression (markers associated with T cell activation and HIV-1 disease progression 
[51]) were measured by multi-color flow cytometry. TCR-mediated stimulation of LPMC, in 
the absence of butyrate, induced significant increases in the percentage of LP CD4 T cells 
that had proliferated and expressed CD25 and co-expressed HLA-DR and CD38 (Fig 4.2a). 
Increasing concentrations of butyrate led to a decrease in the percentage of proliferated LP 
CD4 T cells in a dose-dependent manner (Fig. 4.2a). Butyrate also decreased the 
percentage of LP CD4 T cells that expressed CD25 and co-expressed HLA-DR and CD38 in 
a concentration-dependent manner with significant decreases observed at levels ≥0.25mM, 
(Fig. 4.2a). In the absence of exogenous stimulation, the addition of butyrate to total LPMC 
did not impact proliferation or HLA-DR and CD38 co-expression on LP CD4 T cells; 
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however, butyrate increased the expression of CD25 on LP CD4 T cells by 1.4-fold at 
concentrations of ≥0.125mM.  Given that butyrate is known to promote the differentiation of 
Foxp3+ T regulatory cells[194, 195, 215],  which also express high levels of CD25 [277], 
expression of Foxp3 by LP CD4 T cells in response to butyrate alone was measured.  The 
addition of butyrate to LPMC cultures without exogenous stimulation did not result in 
increased percentages of Foxp3-expressing LP CD4 T cells after four days of culture (Fig 
4.3).  
To determine if the impact of butyrate on TCR-mediated proliferation and activation 
of LP CD4 T cells in LPMC  occurred directly on T cells or required signals from non-T cells, 
negatively selected LP CD4 T cells were exposed to butyrate in the presence and absence 
of TCR stimulation.  TCR bead stimulation of purified LP CD4 T cells in the absence of 
butyrate resulted in significantly increased percentages of proliferated LP CD4 T cells and 
those that expressed CD25 and co-expressed HLA-DR and CD38 (Fig 4.2b).  Butyrate 
directly reduced TCR-mediated LP CD4 T cell proliferation and CD25 expression on LP CD4 
T cells in a dose-dependent manner similar to that observed in LPMC cultures (Fig 4.2b). 
Butyrate had a minimal direct effect on co-expression of HLA-DR and CD38 on purified CD4 
T cells relative to that seen in LPMC cultures. Co-expression of HLA-DR and CD38  on LP 
CD4 T cells were decreased in the presence of butyrate 1.39-fold compared to 1.72-fold in 
cultures with total LPMC at 0.5mM  (Fig 4.2b). In the absence of TCR stimulation, the 
addition of butyrate directly increased the expression of CD25 on LP CD4 T cells in a dose-
dependent manner (Fig 4.2b).   
Timing of Butyrate Exposure and TCR Stimulation is Important for the Inhibition of LP 
CD4 T Cell Proliferation. 
To determine if the timing of butyrate exposure was critical to butyrate’s 
immunomodulatory activity on LP CD4 T cell proliferation, butyrate was added at various 




Figure 4.1. Total LPMC viability after exposure to butyrate 
LPMC were exposed to butyrate (0.0625mM - 4mM) for four days and total LPMC viability 



















beads to total LPMC cultures (Fig. 4.2c, 4.2d). For these assays, butyrate was added at 
0.5mM, the dose at which the maximum immunomodulatory effect on LP T cell proliferation 
was observed (Fig. 4.2a). Exposure of LPMC to butyrate for ≤18hrs before TCR-mediated 
stimulation resulted in equivalent levels of LP CD4 T cell proliferation as observed when 
butyrate was added simultaneously (0hrs) with TCR stimulatory beads (Fig 4.2c). For the 
post-treatment assays, the addition of butyrate 6hrs after TCR-induced stimulation 
decreased proliferation to similar levels as those when butyrate was added simultaneously 
with TCR stimulation (Fig. 4.2d).  However, the addition of butyrate at or after 18hrs of TCR 
stimulation limited butyrate inhibition of LP CD4 T cell proliferation, although the levels of 
proliferation were still lower than in the absence of butyrate (Fig 4.2d). 
Higher Concentrations of Propionate and Acetate Relative to Butyrate were Required 
to Similarly Inhibit LP CD4 T Cell Activation and Proliferation.  
To understand if butyrate’s immunomodulatory effects on TCR-mediated LP CD4 T 
proliferation and activation were shared by other SCFAs found in the gut lumen, total LPMC 
were similarly exposed to varying concentrations of acetate and propionate [166, 167]. 
Acetate and propionate decreased LP CD4 T cell proliferation and activation (percentages 
of CD25+  and HLA-DR+ CD38+ co-expressing LP CD4 T cells) in a concentration-dependent 
manner albeit at higher concentrations than butyrate (Fig 4.4a-c). Unlike butyrate, acetate 
and propionate had no impact on the frequency of CD25+ LP CD4 T cells in the absence of 
TCR stimulation. However, like butyrate, acetate and propionate had minimal effect on LP 
CD4 T cell activation (frequency of HLA-DR and CD38 co-expressing)  and proliferation in 
the absence of TCR stimulation(data not shown).   
Butyrate’s Inhibition of LP CD4 T Cell Activation and Proliferation is likely Mediated 
by HDAC Inhibition  
To determine if butyrate, a known class I  and II HDACi [180, 278], inhibited TCR-










Figure 4.2. Butyrate reduces LP T cell activation and proliferation in a dose-
dependent manner 
Lamina propria mononuclear cells (LPMC) were cultured with or without TCR stimulating 
beads and butyrate (0.0625-0.5mM) for four days and levels of T cell activation and 
proliferation determined (n=3). Changes in the percentages of CFSE
dim
 LP CD4 T cells and 
those expressing CD25 and co-expressing CD38 and HLA-DR were assessed from cultures 
with total LPMC (A) and purified LP CD4 T cells (B) using multi-color flow cytometry. FM2 
(Fluorescence minus two) and isotype control values have been subtracted. Determination 
of the importance of the timing of butyrate addition to TCR bead activated cultures was 
carried out on total LPMC cultures and levels of CFSE
dim
 cells were enumerated by flow 
cytometry after 4-day cultures.  For the assays examining the importance of butyrate pre-
treatment, LPMC were incubated with butyrate for 0, 2, 6 and 18 hours before the addition of 
TCR activating beads and cultured for four days post activation(C). For the assays 
examining the importance of butyrate post-treatment, LPMC were activated with TCR 
activating beads and then incubated with butyrate for 0, 6, 18 and 36 hours for the 
remainder of the 4-day incubation(n=3) (D). Statistical significance was determined using 
one-way ANOVA with Dunnett’s multiple comparison tests to 0mM butyrate or 0hr timepoint. 



















Figure 4.3. Examination of FOXP3+ CD25+ LP CD4 T cells after the addition of 
butyrate. 
LPMC were cultured with butyrate for four days and frequency of a.) CD25+ and b.) 
FOXP3+CD25+ LP CD4 T cells was determined(n=3) by multicolor flow cytometry. For CD4 
Foxp3 staining the following gating strategy was used: viable, lymphocytes, singlets, CD3+, 
CD4+ and CD25+Foxp3+. Isotypes were used, and isotype values were removed from the 
final reported data. Data are mean values, and statistical significance was determined using 
either paired T-tests(a.) or one-way ANOVA with Dunnett’s multiple comparison tests to 
































Figure 4.4. Propionate and Acetate both Decrease TCR Bead Driven LP CD4 T Cell 
Activation and Proliferation. 
LPMC were cultured with or without TCR stimulating beads and butyrate (0.5mM), acetate 
(0.25-10mM) or propionate (0.25-2mM) for four days and levels of T cell activation and 
proliferation were determined (n=3). Changes in the percentages of CFSEdim LP CD4 T cells 
and those expressing CD25 and co-expressing CD38 and HLA-DR were assessed from 
cultures with total LPMC using multi-color flow cytometry. FM2(HLA-DR and CD25) and 
isotype control values have been subtracted. Data are mean values and statistical 
significance was determined using one-way ANOVA with Dunnett’s multiple comparison 











acetylation of histone 3 lysine 9 (H3K9), an indirect indicator of HDAC inhibition[179], were 
measured in LP CD4 T cells by multicolor flow cytometry. Twenty-four-hour exposure of 
unstimulated and TCR-stimulated LPMC to butyrate (0.5mM) resulted in significant 
increases in histone acetylation in LP CD4 T cells relative to controls without butyrate (Fig 
4.5a). Butyrate-induced histone acetylation levels to similar extents in both TCR-stimulated 
and no stimulation conditions.  Butyrate-mediated increases in histone acetylation in LP 
CD4 T cells in the absence of activation were confirmed by western blot (Fig 4.6b). 
The ability of a panel of known class I specific HDAC inhibitors (apicidin and MGCD) 
and pan HDAC inhibitors (TSA and ITF2357) to phenocopy butyrate’s effect on LP CD4 T 
cell proliferation was next investigated. Initial studies were carried out to determine the 
maximal dose of each HDAC inhibitor that did not induce toxicity (data not shown), and 
these maximal doses were used in subsequent assays. The addition of apicidin and MGCD 
decreased LP CD4 T cell proliferation to a greater degree than the addition of either pan 
HDAC inhibitor (Fig 4.5b).  The impact of apicidin on TCR mediated LP CD4 T cell activation 
and proliferation were next tested across a dose range (25-100nM) (Fig 4.5c). Apicidin 
decreased LP CD4 T cell proliferation and the expression of CD25 and co-expression of 
HLA-DR and CD38 on LP CD4 T cells in a dose-dependent manner similar to butyrate (Fig 
4.5c).  In the absence of TCR stimulation, apicidin had little impact on LP CD4 T proliferation 
and the percentages of LP CD4 T cells expressing HLA-DR and CD38.  However, similar to 
the observations of CD25 expression in the presence of butyrate, the percentage of CD25+ 
LP CD4 T cells increased on average 1.5-fold at all concentrations of apicidin tested (Fig 
4.5c). To determine if apicidin also phenocopied butyrate’s ability to act directly on LP CD4 
T cells, the maximal dose of apicidin (100nM) was added to purified LP CD4 T cells in the 
presence of TCR-stimulatory beads (Fig. 4.5d). Apicidin decreased LP CD4 T cell 





Figure 4.5 Butyrate’s HDACi Activity likely Plays a Role in its Immunomodulatory 









Figure 4.5 Butyrate’s HDACi Activity likely Plays a Role in its Immunomodulatory 
Effect on Activated LP CD4 T Cells.  
LPMC cultured with or without TCR stimulating beads and butyrate (0.5mM) for 24 hours 
and levels of histone H3 lysine residue 9 acetylation levels were measured by intracellular 
flow cytometry(n=3). Butyrate driven changes in the mean fluorescence intensity of acH3K9 
were compared to media controls using paired T-tests to determine significance(A). A panel 
of known HDACi was assayed for the ability to decrease LP CD4 T cell proliferation 
(CFSEdim) in total LPMC cultures stimulated with TCR stimulating beads, statistical 
significance was determined by comparing treatment condition to media control (B). Dose-
dependent responses of apicidin (25-100nM) were assayed in total LPMC activated with 
TCR beads and percentages of CFSEdim LP CD4 T cells and those expressing CD25 and 
co-expressing CD38 and HLA-DR were assessed using multi-color flow cytometry(n=3) (C). 
FM2(HLA-DR and CD25) and isotype control values have been subtracted. Purified LP CD4 
T cells were exposed to butyrate 0.5mM, apicidin 100nM or media control in the setting of 
TCR stimulation and the percentages of CFSEdim LP CD4 T cells and those expressing 
CD25 and co-expressing CD38 and HLA-DR were assessed using multi-color flow 
cytometry(n=4) (D). FM2 (HLA-DR and CD25) and isotype control values have been 
subtracted. Statistical significance was determined using raw data values and comparison of 
treatment condition to media controls by one-way ANOVA with Dunnett’s multiple 
comparison tests to 0 nM apicidin or paired T-tests. Data represented as means, bars 



















Figure 4.6. Butyrate Increases LP CD4 T Cell  Histone Acetylation Levels (acH3K9) 
Purified LP CD4 T cells were exposed to exogenous butyrate for 24 hours,  and H3K9 levels 
were evaluated by western blot at 0.125- and 0.5-mM butyrate. P (n=3).  OD values were 




















(Fig. 4.5d).  Similarly, apicidin also decreased the percentage of LP CD4 T cells expressing 
CD25 and co-expressing HLA-DR and CD38 (Fig 4.5d).  
Known Butyrate Receptors, GPR109a and GPR43, are Minimally Expressed on LP 
CD4 T Cells. 
To determine if GPR signaling might contribute to the actions of butyrate on LP CD4 
T cell activation and proliferation, surface protein expression of GPR109a and GPR43 on LP 
CD4 T cells directly ex vivo (baseline) and after TCR bead stimulation and butyrate 
exposure (4 days) was evaluated by multi-color flow cytometry (Fig 4.7a). Low percentages 
of LP CD4 T cells expressed GPR109a (mean 0.5% of total LP CD4 T cells ±0.01% SEM) 
and GPR43 (1.0% ± 0.6% SEM) at baseline (Fig 4.7b). TCR-bead stimulation of LPMC 
significantly increased the percentages of GPR43-expressing  LP CD4 T cells, although 
these percentages remained low (<5% of total LP CD4 T cells). The addition of butyrate did 
not further alter expression (Fig 4.7c). Percentages of GPR109a+ LP CD4 T cells also 
increased with TCR stimulation. Similar to GPR43, GPR109a-expressing LP CD4 T cells 
constituted a very small fraction of total LP CD4 T cells (Fig. 4.7c). Percentages of 
GPR109a were significantly decreased in the presence of butyrate relative to no butyrate, in 
both TCR-stimulated and unstimulated conditions (Fig 4.7c).  
LP Th17 Cell Proliferation is Decreased at Lower Concentrations of Butyrate Relative 
to other Th Subsets.  
The impact of butyrate on the production of T helper cytokines from purified LP CD4 
T cells was next assayed. Butyrate decreased IL-17 production from TCR stimulated LP 
CD4 T cells in a dose-dependent manner. IFNγ and IL-2 production were similarly 
decreased by butyrate with the greatest effect at 0.5mM (Figure 4.8a). The impact of 
butyrate on the proliferative capacity of Th cell subsets( Th1, Th17, and Th22) was next 
assessed by multicolor flow cytometry. TCR stimulation (in the absence of butyrate) drove 




Figure 4.7. LP CD4 T Cells Express Low Levels of GPR43 and GPR109a 
Example flow stain profiled for GPR43 and GPR109a on LP CD4 T cells. Conditions 
represented are baseline expression and cells cultured for four days in the following 
conditions Media, Media + TCR stimulating beads, Butyrate (0.5mM) and butyrate (0.5mM) 
+ TCR stimulating beads (A). Summary data of GPR43 and GPR109a on LP CD4 T cells on 
baseline cells (B) and cultured cells. Data are mean values, and statistical significance was 

















with no stimulation. (Fig 4.8b). The addition of butyrate significantly decreased the 
proliferation of all Th subsets at concentrations ≥0.125mM (Fig 4.8b). To determine if there 
were differences in the concentrations at which butyrate inhibited the proliferation of each Th 
subset by 50%, the half maximal inhibitory concentration (IC50) values were calculated. 
Th17 cells had the lowest IC50 (0.140mM) while Th1 and Th22 subsets had similar IC50s 
(0.227 and 0.270mM). The IC50 for cells that were IL-17-IL-22-IFNγ- was beyond the tested 
concentrations of butyrate (0.802mM). (Fig 4.8b).   
To determine if the lower IC50 for butyrate seen in gut Th17 cells is specific to the 
gut or reflected a more general response of both tissue and peripheral Th cells, the impact 
of butyrate on TCR-mediated proliferation of Th cells in PB mononuclear cells (PBMC) was 
tested (Fig 4.9). Butyrate significantly decreased the proliferation of all Th subsets at 
concentrations ≥0.125mM. However, in contrast to LP Th subsets, butyrate inhibited PB 
Th17 (IC50: 0.167) and Th1 (IC50: 0.178mM) cells to a similar extent as gut Th17 cells, 
while Th22 (IC50: 0.260mM) was more similar to the IC50s of the Th1 and Th22 cells in the 
gut. Unlike in the gut, PB IL-17-IL-22-IFNγ- cells were the most sensitive to butyrate (IC50: 
0.127)( Fig 4.9).  
Butyrate Enhances HIV-1 Infection of LP CD4 T Cells at Lower Concentrations. 
We previously reported that high concentrations of butyrate (2mM) decreased 
productive HIV-1 infection of LP CD4 T cells driven by exposure to bacterial stimulation 
[229] at concentrations that maximally inhibited LP CD4 T cell activation. Here I tested 
butyrate over a wider physiologic concentration range and with direct stimulation of LP CD4 
T cells with TCR stimulation. The percentage of productively infected CD4 T cells was 
determined by the examination of LP CD4 T cells that, expressed the HIV-1 viral capsid 
protein (p24) by multicolor flow cytometry. Exposure of LPMC to TCR-beads significantly 
increased the percentage of productively infected CD4 T cells in 4-day cultures (Fig 4.10). 




Figure 4.8. Butyrate Decreases T Helper Cytokine Production and the Proliferation of 
Gut T Helper Cells 
Purified LP CD4 T cells were cultured with or without TCR stimulating beads and butyrate 
(0.125-0.5mM) for four days and levels of secreted IL-17, IFNγ and IL-2 in the supernatants 
were quantified by ELISA(n=3) (A). Butyrate’s impact on TCR bead driven T helper subset 
proliferation was characterized in total LPMC exposed to butyrate (0.0625-0.5mM) for four 
days. Proliferation was determined by CFSE labeling and T helper subsets were identified 
by cytokine (IFNγ, IL-17 and IL-22) production after exposure to PMA and ionomycin 
stimulation for the last 4 hours of culture(n=6)(B). FMO and isotype control values have 
been subtracted. IC50 values were calculated, and statistical significance was determined 
using one-way ANOVA(*P<0.05) and was computed using raw data values and comparison 
of treatment condition to media controls. Data represented as means, bars represent 









Figure 4.9. Butyrate Reduces PB T Cell Activation and Proliferation in a Dose-
dependent Manner. 
Butyrate’s impact on TCR bead driven T helper subset proliferation was characterized in 
total PBMC exposed to butyrate (0.0625-0.5mM) for four days. Proliferation was determined 
by CFSE labeling, and T helper subsets were identified by cytokine (IFNγ, IL-17, and IL-22) 
production after exposure to PMA and ionomycin stimulation + Golgi plug for the last 4 hours 
of culture. Isotype control values have been subtracted. IC50 values were calculated, and 
statistical significance was determined using one-way ANOVA and Dunnett’s multiple 















resulted in a further increase in the percentage of productively infected LP CD4 T cells. 
Conversely, higher butyrate concentrations (≥0.25mM) led to reductions in the percentage of 
productively infected LP CD4 T cells with 0.5mM butyrate suppressing infection to baseline 
levels (Fig 4.10a). To measure the effect of butyrate on the release of infectious virions 
throughout the 4-day culture period, infectious virions in the supernatants were next 
quantified. In agreement with percentages of p24-expressing LP CD4 T cells in the setting of 
TCR-stimulation (Fig 4.10a), increased infectious HIV-1 titers were observed at lower 
concentrations of butyrate whereas reductions at 0.5mM to levels seen in the absence of 
TCR-stimulation were noted (Fig .4). In the absence of TCR-stimulation, there was an 
observed increase in the production of infectious virions at 0.125mM butyrate (Fig 4.10b) 
which was not reflected in the percentages of p24+ LP CD4 T cells (Fig 4.10a). To 
determine if butyrate was acting directly on LP CD4 T cells to influence infection levels, 
assays using purified LP CD4 T were carried out. TCR-stimulation in the absence of 
butyrate increased percentages of p24-expressing LP CD4 T cells (Fig 4.10c) and infectious 
HIV-1 titers (Fig 4.10d). In contrast to total LPMC cultures (Fig 4.10a, b), low dose (≤ 
0.125mM) butyrate did not increase the percentage of p24-expressing purified CD4 T cells 
or infectious HIV-1 titers (Fig 4.10c-d) with lower expression and titers observed at 0.125mM 
versus 0mM butyrate. Higher concentrations of butyrate (≥0.25mM) decreased p24+ LP 
CD4 T cells and infectious virus titers (Fig 4.10 c-d).  
 The percentage of productively infected LP Th cell subsets in the presence of 
butyrate was next analyzed. LPMC activation promoted similar increases in the percentage 
of p24-expressing Th17, Th1 and Th22 above conditions without stimulation (Fig 4.10e). 
Butyrate at low doses increased infection of Th17, Th1 and Th22 cells with significance 
reached at 0.0625mM for Th22 and 0.125mM for Th17 cells.  Higher concentrations of 
butyrate decreased percentages of all p24-expressing Th cell subsets relative to no butyrate 




Figure 4.10. High and Low Concentrations of Butyrate Differentially Alter LP CD4 T 






Figure 4.10. High and Low Concentrations of Butyrate Differentially Alter LP CD4 T 
Cell HIV-1 Infection Levels. 
LPMC were spinoculated with the CCR5-tropic transmitted/founder virus CH40 and cultured 
with or without TCR stimulating beads and butyrate (0.0625- 0.5mM) for four days and levels 
of LP  CD4 T cell productive infection(p24) (n=6) were assessed using multi-color flow 
cytometry (A). Mock-infected control values have been subtracted. HIV-1 infectious viral 
titers in culture supernatants were assayed by TZM-bl and values are reported as relative 
luciferase units/per ml (n=5)(B). To determine if butyrate directly impacts LP CD4 T cell 
infection, purified LP CD4 T cells were spinoculated with CCR5-tropic transmitted/founder 
virus CH40 and cultured with or without TCR stimulating beads and butyrate (0.0625- 
0.5mM) for 4 days and levels of LP T CD4 T cell productive infection(p24) were quantified by 
multi-color flow cytometry(n=4)(C). HIV-1 infectious viral titers in culture supernatants from 
cultures with purified LP CD4 T cells were assayed by TZM-bl (D). Frequencies of 
productively infected T helper subsets were determined in total LPMC spinoculated with 
CH40, stimulated with TCR stimulating beads and exposed to a range of butyrate (0.0625-
0.5mM) and cultured for four days. T helper subsets were determined by intracellular 
cytokine staining after addition of PMA and ionomycin + Golgi plug during the last 4 hours of 
culture (n=6)(E). Statistical significance was determined using one-way ANOVA with 
Dunnett’s multiple comparison tests and was computed using raw data values and 
comparison of treatment condition to 0mM controls. Data represented as means, bars 



















Figure 4.11. Butyrate does not Alter the Frequencies of Productively Infected T Helper 
Subsets in the Absence of Activation.  
Frequencies of productively infected T helper subsets were determined in total LPMC 
spinoculated with CH40, stimulated with TCR beads and exposed to a range of butyrate 
(0.0625-0.5mM) and cultured for four days. T helper subsets were determined by 
intracellular cytokine staining after addition of PMA/Ionomycin + Golgi plug during the last 4 














the other Th subsets in conditions with TCR stimulation, but like other subsets, the 
frequency of productively infected cells increased at 0.125mM. In the absence of 
stimulation, butyrate alone did not substantially alter the frequency of p24+ Th cells (Fig 
4.11).    
Low Dose Butyrate Increases the Expression of CCR5 on Activated LP CD4 T Cells 
and HIV-1 Viral Entry. 
Expression levels of known HIV-1 co-receptors are known to alter the infectibility of 
CD4 T cells[14, 40, 279].To investigate if increased LP CD4 T cell infection observed 
following low dose butyrate exposure was related to increased expression of the canonical 
HIV-1 co-receptor CCR5 and CD4 [280], the impact of butyrate on surface expression of 
these molecules was determined using multi-color flow cytometry.  TCR stimulation of total 
LPMC in the absence of butyrate significantly increased CD4 expression(Fig 4.12a). 
Butyrate decreased CD4 expression at  concentrations ≥0.125mM (Fig 4.12a). However, the 
addition of butyrate to total LPMC in the absence of exogenous TCR stimulation did not 
significantly impact on CD4 expression. Conversely, butyrate increased CCR5 expression at 
lower concentrations (0.125mM) in the presence of TCR stimulation, on average by 1.42-
fold (Fig 4.12a). In the absence of TCR stimulation, CCR5 expression increased on average 
by 1.29-fold at 0.125mM but did not reach statistical significance (Fig 4.12a).  
To determine if the effect of low dose butyrate on CCR5 expression was via a direct 
effect on butyrate on these cells we next  tested the ability of butyrate, at concentrations that 
had the most differential response on HIV-1 infection and CCR5 expression, for the ability to 
alter CCR5 and CD4 expression on purified LP CD4 T cells. In keeping with observations for 
total LPMC, TCR stimulation alone of purified CD4 T cells resulted in significant increases in 
CD4 expression relative to no stimulation but did not significantly increase the expression of 
CCR5 (Fig 4.12b). Similar to total LPMC, CD4 expression on purified CD4 cells was 
decreased by butyrate in a dose-dependent manner (Fig 4.12b). However, in contrast to 
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total LPMC, low dose butyrate (0.125mM) did not increase CCR5 and  high dose (0.5mM) 
decreased CCR5 expression(Fig 4.12b).  
 To better understand the impact of butyrate on the HIV-1 lifecycle, both viral 
transcription (gag) and entry (HIV-1 RU-5) were next studied by qPCR. Butyrate is known to 
promote the transcription of HIV-1 virus in latently infected CD4 T cells[281]. Therefore HIV-
1 transcription (gag RNA) was measured in activated LP CD4 T cells exposed to butyrate. 
The addition of butyrate resulted in a dose-dependent increase in HIV-1 gag RNA(Fig 4.12c)  
HIV-1 RU-5 DNA represents the early DNA products of reverse transcription and can be 
used to quantify the amount of HIV-1 viral entry and reverse transcription [282]. Since the 
impact of butyrate on LP CD4 T cell infection and CCR5 expression was seen in the setting 
of other cells in the LPMC, we exposed HIV-1 infected LPMC to butyrate and TCR 
stimulation for 24 hours and then sorted the CD4 T cells. I next quantified HIV-1 RU-5 DNA 
levels in these purified LP CD4 T cells. RU-5 DNA levels increased at 0.125mM butyrate, 
while there were no observable effects at higher concentrations (Fig 4.12d). 
Apicidin Decreases LP CD4 T Cell Productive Infection and CD4 Expression 
To evaluate if butyrate’s effect on LP CD4 T cell infection was mediated via HDAC 
inhibition, the impact of apicidin on LP CD4 T cell HIV-1 infection and HIV-1 co-receptor 
expression was next evaluated (Fig 4.13). In keeping with butyrate’s ability to decrease 
productive infection at higher concentrations, apicidin in the setting of TCR stimulation 
reduced the percentage of p24+ LP CD4 T cells at concentrations ≥ 25mM (Figure 4.13). 
The addition of apicidin in the setting of TCR-stimulation did not drive changes in CCR5 
expression, however similar to butyrate at higher concentrations it did decrease CD4 
















Figure 4.12 Butyrate Alters HIV-1 Co-receptor Expression on LP CD4 T Cells and Viral 
Entry 
LPMC were cultured with or without TCR stimulating beads and butyrate (0.0625-0.5mM) for 
four days, and the levels of CCR5 and CD4 expression (MFI) were assessed using multi-
color flow cytometry (N=6).  Isotype control values have been subtracted for CCR5(A). 
Purified LP CD4 T cells were similarly stimulated with TCR stimulating beads and exposed 
to butyrate (0.125 and 0.5mM), and CCR5 and CD4 expression were determined(B). Data is 
displayed as raw MFI or frequency values. (C) Viral entry assay and reverse transcription, 
LPMC were infected for 24 hour, and the presence of HIV-1 RU-5 DNA was quantified in LP 
CD4 T cells. HIV-1 RU-5 DNA copy number was normalized to RNaseP cycle number 
(N=4). (D) HIV-1 gag RNA PCR assay. LPMC were spinoculated with CH40 HIV-1, exposed 
to increasing concentrations of butyrate, amprenavir or raltegravir and TCR stimulation for 
48 hours. After 48 hours, LP CD4 T cells were isolated, and qPCR for HIV-1 gag RNA and 
GAPDH were carried out. Statistical significance was determined using one-way ANOVA 
with Dunnett’s multiple comparison tests to 0mM butyrate. Data represented as means, bars 





















Figure 4.13. Apicidin Decreases LP CD4 T Cell Productive Infection and CD4 
Expression at High Concentrations.  
 A.) CH40 infected LPMC were cultured with TCR stimulating beads and apicidin (25-
100nM) for four days, and levels of productive infection (p24)were assessed using multi-
color flow cytometry. Mock control values have been subtracted  (n=3). B.) Total LPMC were 
activated with TCR stimulating beads and exposed to apicidin for four days (25-100nM), and 
CCR5 and CD4 expression were determined by MFI. CCR5 isotype expression values were 
removed from data. Data are mean values, and statistical significance was determined using 
one-way ANOVA with Dunnett’s multiple comparison tests(*P<0.05)  relative to 0nM apicidin 














Low abundances of BPB have been reported in the gut mucosa and stool of 
PLWH[103, 145, 146, 229, 283]. However, studies extensively probing how low tissue 
concentrations of butyrate may impact local gut immunity, particularly gut CD4 T cells, in the 
setting of HIV-1 infection and the mechanisms by which this occurs, are limited. In this 
chapter, I utilized an in vitro human LPMC model to investigate the impact of butyrate on LP 
CD4 T cell function both in the presence and absence of HIV-1. The responses to various 
concentrations of butyrate that would broadly reflect “low” and “high” physiologic butyrate 
tissue concentrations were used to investigate the impact of butyrate in this model. Butyrate 
directly and in a concentration-dependent manner decreased TCR mediated LP CD4 T cell 
activation and proliferation likely by acting as an HDAC inhibitor. Furthermore, while butyrate 
decreased the proliferation of all gut Th subsets enumerated there was an increased 
sensitivity to butyrate’s anti-proliferative effect in the Th17 subset which was not reflected in 
PB Th subsets highlighting the gut-specificity of butyrate’s actions. A caveat to these 
findings is that the more sensitive subsets in both the LP and PB Th cells were the subsets 
that had the lowest average proliferation in response to TCR stimulation. This may indicate 
that LP T helper cells that are less responsive to TCR stimulation are more sensitive to 
butyrate. These findings have broad applicability to other diseases such as irritable bowel 
disease (IBD) that are characterized by low abundances of BPB and marked activation of 
Th1 and Th17 cells in the gut mucosa[135, 136, 284]. In these settings, higher 
concentrations of butyrate would likely dampen Th17 and Th1 activation and proliferation in 
the gut mucosa thus limiting the overt T cell driven inflammation that is characteristic of 
these diseases. 
A key finding of in this chapter is the apparent uncoupling of HIV-1 infection and LP 
CD4 T cell activation at lower concentrations of butyrate whereby low dose butyrate 
decreased LP CD4 T cell activation but increased productive infection of LP CD4 T cells 
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which was reflected in increased infection of all Th subsets. Although CD4 T cell activation is 
generally considered to be tightly associated with HIV-1 infection both in vitro and in vivo 
[285-288], we had previously demonstrated enteric bacteria-driven increases in LP CD4 T 
cell infection in vitro also occurred in the absence of extensive LP CD4 T cell activation[156].  
In this setting, the increased infection was associated with increased CCR5 expression on 
LP CD4 T cells in response to signals from other LPMC.  Intriguingly, increased infection at 
low doses of butyrate was also similarly linked to increased CCR5 expression and viral 
entry, but this effect was lost in the absence of other LPMC suggesting increased CCR5 
expression was mediated via butyrate’s effect on other cell types in the LPMC.  Therefore, 
the regulation of cytokines produced by these cells could be a potential mechanism by 
which butyrate alters CCR5 expression indirectly. Butyrate has been shown to induce IL-10 
production by antigen presenting cells(APCs) in vitro [225, 263] and other studies have 
implicated IL-10 in increasing human PB CD4 T cell CCR5 expression[289]. Taken together, 
these studies suggest a similar cross-talk between low dose butyrate, APCs and T cells 
could be driving increased CCR5 expression on LP CD4 T cells at lower concentrations of 
butyrate. Additionally, these studies also demonstrate that the increase in productively 
infected LP CD4 T cells is not reflective of an increase in viral transcription, which further 
affirms the observation the increase in productive HIV-1 infection by low concentrations of 
butyrate is CD4 T cell and HDAC inhibitor independent. Studies are underway to dissect the 
specific mechanisms by which low dose butyrate regulates factors that promote increased 
CCR5 expression and HIV-1 viral entry into LP CD4 T cells.   
Gut mucosal Th cells are essential mediators of intestinal barrier integrity, and 
dysregulation of their function and frequencies is a hallmark of inflammatory disorders of the 
gut mucosa[62]. For example, increased frequencies of cytokine-producing Th1 and Th17 
cells in the gut mucosa are noted to be a key feature of IBD[284].  In this current study, 
butyrate decreased the proliferation of all Th cell subsets; however, the IC50 of Th17 
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proliferation occurred at lower doses of butyrate.  There are several potential explanations 
for the sensitivity of Th17 cells to butyrate relative to other Th subsets in the gut mucosa. 
Firstly, Th17 cells may have higher expression levels of know butyrate receptors such as 
GPR43 and GPR109a.  Indeed, although we observed the low frequency of GPR 
expression on total LP CD4 T cells,  it is possible that this population of GPR-expressing 
CD4 T cells represent the similarly small fraction of Th17 cells found in the LP.  
Furthermore, CD147, a component of MCT-1, a known cellular butyrate transporter, was 
shown to be expressed on Th17 [184, 290]. Thus, increased sensitivity of LP Th17 cells may 
also reflect an increased ability to transport butyrate into these cells relative to other Th 
subsets.   
Although this study primarily focused on butyrate’s ability to modulate LP CD4 T cell 
function in vitro, we also investigated functional responses after exposure to acetate and 
propionate,  the other primary SCFAs found in the human gut [166, 167].  Both acetate and 
propionate decreased LP CD4 T cell activation and proliferation, albeit at higher 
concentrations than butyrate. This differential impact on LP T cell function may reflect the 
ability of these to inhibit class I HDAC activity since all 3 inhibit this class of HDACs, but 
butyrate is known to be the most potent. [85, 180, 181, 291].  Our observations also suggest 
that there may be redundancies in the ability of these SCFAs to modulate LP CD4 T cell 
responses in the gut mucosa. Thus, lower concentrations of one may have limited 
detrimental impact if higher concentrations of the other SCFAs are present.    
While several studies have demonstrated butyrate’s ability to inhibit CD4 T cell 
responses when added concurrently with stimulation[190-192, 195, 196, 229], the ability of 
butyrate to alter existing LP CD4 T cell activation has yet to be thoroughly studied. We 
demonstrated that butyrate’s immunomodulatory effects are dependent on the addition of 
butyrate concurrently with LP CD4 T cell activation.  The observations that butyrate’s 
immunomodulatory effects are lost if LP CD4 T cells are exposed to butyrate after 18hrs of 
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stimulation have significance in the clinical setting. Since the efficacy of interventions to 
increase butyrate may be diminished if T cell activation is well established and therefore in 
this setting butyrate would likely only prevent activation of newly recruited T cells to the gut 
mucosa. Indeed, this may explain the conflicting observations in butyrate intervention in IBD 
patients where some studies demonstrated clinical improvement while others showed no 
effect from the treatments [292-294].   
 In conclusion, this data outlined in this chapter is the first to demonstrate that 
butyrate can have differential impacts on gut human LP CD4 T cell activation and HIV-1 
infection over a physiologic concentration range in vitro. To translate these findings into the 
clinical setting, future studies investigating the impact of butyrate administration during HIV-
1 infection on inflammation and  T cells activation both in the mucosa and periphery need to 




















ADDITIONAL MECHANISMS OF BUTYRATE’S IMMUNOMODULATORY EFFECTS ON 
LP CD4 T CELL ACTIVATION AND PROLIFERATION 
 
Background 
 Butyrate has been demonstrated to alter cell function through multiple pathways that 
include HDACi and signaling though GPRs and PPARγ[178, 185, 205, 207]. In the previous 
chapter, I determined the importance of HDACi and GPR signaling in the 
immunomodulatory effect of butyrate on TCR driven activation of LP CD4 T cells. These 
studies indicated that low frequencies of LP CD4 T cells expressed GPR43 and GPR109a, 
which indicated that this was not likely the dominant pathway by which butyrate functioned 
in this cell type. Next, the role of HDAC inhibition was investigated, which demonstrated that 
butyrate increased histone acetylation levels in LP CD4 T cells and its effects on TCR 
stimulation driven LP CD4 T cell activation and proliferation were phenocopied by a class I 
HDACi. While not conclusive, these data indicate that inhibition of class I HDAC proteins are 
likely the primary mechanism by which butyrate alter LP CD4 T cell activation and 
proliferation. 
 In this chapter, I attempted to further confirm the role of HDAC inhibition using a 
histone acetyltransferase inhibitor (HATi). A HATi was used to determine if the increases in 
histone acetylation driven by butyrate were responsible for the observed changes in TCR 
driven LP CD4 T cell proliferation. HAT proteins are the counterpart to HDAC proteins in the 
cell and act to add acetyl groups to histones or other proteins while HDACs remove 
them[179, 272]. When butyrate, a known HDACi, is present the activity of HDACs is 
deceased and thus the acetylation levels in the cell increase due to unopposed HAT activity. 
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Therefore, I tested the ability of a HATi to decrease histone acetylation in our model and 
block the effect of butyrate on LP CD4 T cell proliferation.  
 PPARγ receptor signaling is a relatively understudied pathway by which butyrate has 
been demonstrated to signal. To date, there have been two critical studies that have shown 
a role for butyrate signaling through the PPARγ receptor in colonic epithelial cells[207, 208]. 
The studies demonstrated that butyrate was able to modulate host epithelial gene 
expression and production of reactive nitrogen species through PPARγ signaling. While 
these studies focused exclusively on PPARγ signaling in epithelial cells, there is precedence 
for the immunomodulatory impact of PPARγ signaling in T cells[295, 296]. Therefore, in this 
chapter, I also probed the importance of PPARγ signaling on the effect of butyrate on TCR 
stimulated LP CD4 T cells through the use of both PPARγ agonists and antagonist in the 
LPMC model. 
Results 
Inhibition of Histone Acetyltransferases does not Block the Antiproliferative Effect of 
Butyrate on TCR Stimulated LP CD4 T Cells. 
Increased histone acetylation is a marker for HDAC inhibition and is mediated by the 
activity of HAT proteins[178]. To determine if the inhibition of HAT protein activity with a 
chemical HATi decreased histone 3 lysine 9 (H3K9) acetylation in LP CD4 T cells, LPMC 
were cultured in the presence or absence of 0.5mM butyrate and the p300 HATi C646 for 24 
hours. H3K9 acetylation levels were next determined by multicolor flow cytometry.  The 
addition of butyrate to LPMC resulted in increased H3K9 acetylation in LP CD4 T cells. 
When the HATi was added to cultures with butyrate, there was a consistent decrease in 
H3K9 acetylation after 24 hours of culture (Figure 5.1A).  
 Next, I sought to determine if the addition of the HATi to LPMC cultures with TCR 
stimulation and butyrate blocked the effect of butyrate on proliferation as determined by 




Figure 5.1. HAT Inhibition Decreases Butyrate Driven H3K9 Acetylation but does not 
Impact Butyrate’s Impact on LP CD4 T Cell Proliferation.  
 a.) LPMC were cultured with TCR stimulating beads and butyrate (0.5mM) in the presence 
or absence of a HATi (5µM) for 24 hours, and levels productive H3K9 acetylation was 
assessed using multi-color flow cytometry (n=3). b.) Total LPMC were activated with TCR 
stimulating beads and exposed to butyrate (0-0.5mM) and HATi (5µM) for four days and 
proliferation of LP CD4 T cells was determined by CFSE dilution(n=3). Data are mean 
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0.5mM butyrate and the HATi for four days. The cultures with the HATi were pretreated with 
the HATi for one hour. After four days of culture, the addition of the HATi did not significantly 
reverse the impact of butyrate on TCR driven LP CD4 T cell proliferation(Figure 5.1B) 
PPARγ Agonism Phenocopies the Antiproliferative Effect of Butyrate but is not 
Reversed by a PPARγ Antagonist.  
 Since PPARγ is known to be expressed in CD4 T cells and PPARγ signaling has 
been demonstrated to alter CD4 T cell differentiation and function[295, 296], I next tested 
the impact of PPARγ agonism on TCR stimulation driven LP CD4 T cell proliferation. LPMC 
were stimulated with TCR activating beads in the presence of a dose range of 
Rosiglitazone, a known PPARγ agonist, for four days. Rosiglitazone decreased LP CD4 T 
cell proliferation at the highest non-toxic concentration of 100µM but had little activity at 
lower concentrations(Figure 5.2A).  
 Next, a non-competitive PPARγ antagonist, T 0070907, was tested for the ability to 
block butyrate’s antiproliferative effect in LP CD4 T cells. LPMC were pre-treated with a 
dose range of T 0070907a for 1 hour and then cultured with TCR stimulating beads and 
butyrate (0.125 and 0.5mM) for four days at which time proliferation was determined by 
multicolor flow cytometry. After four days of culture, butyrate decreased TCR stimulation 
driven LP CD4 T cell proliferation, and T 0070907 was unable to inhibit butyrate’s impact. 
An important caveat to this assay was that T 0070907 was unable to inhibit rosiglitazone’s 
impact at 100µM (Figure 5.2B).  
Discussion 
The data presented in this chapter attempted to further clarify the mechanisms by 
which butyrate is inhibiting TCR driven LP CD4 T cell proliferation.  The data presented here 
continue to address the mechanisms by which butyrate alters LP CD4 T cell proliferation. 
There are several important findings highlighted in this chapter. First, the p300 HAT inhibitor 




Figure 5.2. PPARγ Agonism Decreases LP CD4 T Cell Proliferation, but PPARγ does 
not Inhibit this Effect. 
 a.) LPMC were cultured with TCR stimulating beads and butyrate (0.5mM) as well as a 
concentration range of rosiglitazone (0.1-100µM) for four days and proliferation of LP CD4 T 
cells was determined by CFSE dilution using multi-color flow cytometry (n=1). b.) Total 
LPMC were activated with TCR stimulating beads and exposed to butyrate (0.125 and 
0.5mM) and the PPARγ antagonist T 0070907 for four days and proliferation of LP CD4 T 


















butyrate. Also, there is a trend for the inhibition of butyrate’s effect on LP CD4 T cell 
proliferation by the HATi. Due to the small sample size, further assays are warranted to 
determine if the HATi is blocking butyrate’s antiproliferative impact on LP CD4 T cells. 
Furthermore, these assays are confounded by the observation that p300 is involved in 
cellular proliferation and its inhibition can decrease cellular proliferation[297]. In our model, 
the use of a p300 HATi did modestly decrease the proliferative capacity of LP CD4 T cells 
independent of butyrate. Therefore, future studies focused on the impact of HAT inhibition 
on butyrate’s effect on LP CD4 T cell activation and infection may be informative.  
The impact of PPARγ agonism on LP CD4 T cell proliferation was not unexpected 
since PPARγ agonism has been previously demonstrated to dampen the function and 
activation in both mouse and human PB CD4 T cells [295, 296]. While there did appear to 
be an impact of rosiglitazone at the highest concentration tested there are several limitations 
that must be addressed moving forward. First, the sample size must be increased to 
generate statistical differences and LP CD4 T cell activation and HIV-1 infection need to be 
evaluated in addition to proliferation. There also needs to be a broader concentration range 
of rosiglitazone tested centered around 100µM to determine if there are concentration-
dependent effects of rosiglitazone. Lastly, the need for better positive controls for the 
PPARγ antagonist due to the inability of the PPARγ antagonist to block the effect of butyrate 
and rosiglitazone on LP CD4 T cell proliferation.  Collectively, the data presented in this 
chapter indicate that the mechanisms by which butyrate alter LP CD4 T cell activation and 
proliferation are likely multifactorial and more directed and specific assays are warranted to 










Project Rationale and Outline 
Chronic immune activation, infection, and depletion of gut CD4 T cells and dysbiosis 
of the GI tract microbiome are hallmarks of HIV-1 infection and are thought to contribute to 
its progression[22, 100, 112, 274]. The lower relative abundance of BPB species has been 
demonstrated in the colonic mucosal microbiome of PLWH[229]. A key feature of these 
changes is the inverse association of the abundance of these groups of bacteria with 
indicators of local and systemic immune activation as well as microbial translocation and 
viral load[229]. The association of the altered abundance of BPB and gut mucosal 
inflammation has also been determined in other inflammatory conditions of the GI tract such 
as IBD[135-137]. The impact of alterations in butyrate concentrations on gut mucosa T cell 
activation and HIV-1 infectability has yet to be studied in detail.  
 The studies outlined in this thesis had two specific aims. The first aim of this 
thesis was to characterize the effect of exogenous butyrate on enteric pathobiont-driven gut 
mucosal T cell activation and HIV-1 infection. This was followed by the second aim that was 
to carry out mechanistic studies looking at the impact of a range of physiologic butyrate 
concentrations on direct TCR stimulation driven LP CD4 T cell activation and HIV-1 
infection. For the first aim of the thesis, I hypothesized that butyrate would reduce enteric 
bacteria driven LP T cell activation, cytokine production, and HIV-1 infection. For the second 
aim of the thesis, I hypothesized that exposure of LP CD4 T cells to physiologic 
concentrations of butyrate would dampen LP CD4 T cell activation, cytokine production, Th 
subset proliferation, and HIV-1 infection directly and in a concentration-dependent manner 
through its known activity as an HDACi.  
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 Since the detailed results have been presented in previous chapters, I will review the 
major findings from each chapter and discuss the implications of these findings on the 
understanding of HIV-1 pathogenesis and the potential of these findings to inform future 
studies. Furthermore, I also will discuss the limitations of the data presented in this thesis. 
Summary of Major Findings 
In the first aim of this thesis, I aimed to translate findings from the clinical study 
outlined in the introduction[229], by examining the impact of exogenous butyrate on enteric 
pathobiont driven LP T cell activation and HIV-1 using an in vitro model of microbial 
translocation. In these studies, the pathobiont Prevotella stercorea was used to drive LP 
CD4 and CD8 T cell activation, cytokine production, and productive HIV-1 infection. When 
exogenous butyrate was added at a concentration of 2mM, there was a significant decrease 
in both LP CD4 and CD8 activation, production of inflammatory cytokines (IL-17 and IFNγ) 
and productive HIV-1 infection.  
 The purpose of the second aim was to address the impact of butyrate on LP CD4 T 
cell activation, proliferation, and HIV-1 infection and to understand the mechanism by which 
this occurs. In these initial studies, it was determined that butyrate decreased LP CD4 T cell 
activation and proliferation in a dose-dependent manner after four days of culture with the 
maximal effect seen at the highest concentration tested (0.5mM). In the absence of TCR 
stimulation butyrate increased the expression of CD25 on LP CD4 T cells at concentrations  
≥0.125mM. Next, negatively selected LP CD4 T cells were tested similarly to determine if 
the effect of butyrate was mediated directly on an LP CD4 T cell or another cell type in the 
LPMC. Similar to total LPMC, there was a dose-dependent decrease in TCR stimulation 
driven activation and proliferation as well as an increase in CD25 expression in the absence 
of TCR stimulation.  While the concentration-dependent decrease in LP CD4 T cell 
activation and proliferation was expected the increase in the frequency of CD25+ LP CD4 T 
cells in the absence of activation was not. Since butyrate has been demonstrated to 
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promote the differentiation and function of T regulatory cells[194, 195, 215], which have 
higher expression levels of CD25[298], the frequency of FoxP3+ LP CD4 T cells was next 
tested. After four days of culture, butyrate had no observable effect on the frequency of LP 
CD4 T cells that expressed FoxP3. Therefore, butyrate did not alter T regulatory cell 
frequency in our model, and the increase in CD25 expression may reflect the specific 
regulation of CD25 expression by butyrate. 
 Since butyrate acted directly and in a concentration-dependent manner, the 
subsequent assays that were carried out to address aim 2 examined the specificity of the 
effect of butyrate. First, the other primary SCFAs, acetate, and propionate were tested for 
their ability to decrease LP CD4 T cell activation and proliferation over a physiologic 
concentration range[166, 167]. Similar to butyrate, acetate and propionate decreased TCR 
stimulation driven LP CD4 T cell activation and proliferation in a concentration-dependent 
manner. However, the effects of these other SCFA were noted at higher concentrations than 
butyrate. These results indicate the effect of butyrate on LP CD4 T cell activation and 
proliferation are not unique and are shared by other SCFAs in the gut lumen. This 
observation may further inform on the mechanisms by which butyrate alters LP CD4 T cell 
responses since these SCFA share the ability to signal through common surface GPRs and 
function as HDAC inhibitors.  
 Butyrate is known to have multiple pathways by which it alters cell function[228]. Of 
those, the two better studied are HDAC inhibition and signaling through GPRs(GPR109a 
and GPR43)[228]. To explore whether either of these two pathways was involved in 
butyrate’s ability to alter LP CD4 T cell activation and proliferation, the ability of butyrate to 
function as an HDACi was examined. When LPMC were treated with butyrate for 24 hours, 
there was a significant increase in the amount of histone H3 lysine 9 acetylation as 
determined both by flow cytometry and western blot. With confirmation that butyrate was 
acting as an HDACi, the ability of known HDACis to phenocopy butyrate’s effect on LP CD4 
95 
 
T cell activation and proliferation was next examined. These studies demonstrated that class 
I HDACis, notably apicidin, phenocopied butyrate’s ability to directly decrease TCR 
stimulation driven LP CD4 T cell activation and proliferation in a concentration-dependent 
manner. Collectively, these studies indicate that butyrate is likely functioning as an HDACi in 
LP CD4 T cells and the inhibition of class I HDAC proteins is likely the mechanism by which 
butyrate is decreasing LP CD4 T cell activation and proliferation. Ideally, I would confirm 
these observations by blocking specific HDAC proteins either chemically or genetically. 
 Although butyrate was acting as an HDACi in our culture model, there was still a 
possibility that GPR signaling could be an essential component of butyrate’s 
immunomodulatory effect on LP CD4 T cells. To determine if GPR signaling was involved in 
butyrate’s activity in LP CD4 T cells, the expression of GPR43 and GPR109a protein was 
examined on LP CD4 T cells directly ex vivo and after four days of culture with or without 
butyrate and TCR stimulation. While there did appear to be some differences in the 
expression of both GPR43 and GPR109a on LP CD4 T cells after TCR stimulation and 
butyrate exposure, the frequency of LP CD4 T cells that expressed these GPRs was 
generally low (≤4% GPR43 and ≤1% GPR109a) and could not account for the magnitude of 
effects on T cell proliferation and activation. Although, butyrate signaling through GPRs is 
not likely responsible for the observed effect of butyrate on the majority of LP CD4 T cell it 
could impact a smaller subset of cells such as the Th17, Th22 or T regulatory cells. The 
importance of these surface receptors could be further interrogated by using chemical 
antagonist and agonist as well as genetic modulation of their expression.  
 The CD4 T cells that populate the gut mucosa are comprised of unique T helper 
subsets that serve important roles in gut barrier homeostasis[80, 299, 300]. During HIV-1 
infection, gut Th17 and Th22  cells appear to be preferentially infected and depleted, and it 
is thought that the loss of these cells is central to HIV-1 pathogenesis[43, 102, 115]. With 
the importance of Th cells in HIV-1 disease progression, the impact of butyrate on the 
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proliferation of distinct Th subsets in the LPMC was next tested. Consistent with the findings 
in total LP CD4 T cells, butyrate decreased the proliferation of Th1, Th17, Th22 and non-
IFNγ, IL-17, IL-22 producing Th cells in a concentration-dependent manner. Of the subsets 
enumerated, the non-IFNγ, IL-17, IL-22 producing Th cells proliferated the most and Th17 
cells proliferated the least in response to TCR stimulation. With the addition of butyrate, the 
Th17 cells were the most sensitive while the non-IFNγ, IL-17, IL-22 producing Th cells were 
the least sensitive to the anti-proliferative effects of butyrate. Consistent with the higher 
relative sensitivity of LP Th17 cells to the antiproliferative effect of butyrate, the production of 
IL-17 from purified LP CD4 T cells that had been stimulated with TCR beads was decreased 
at lower concentrations than both IL-2 and IFNγ. The observed sensitivity of LP Th17 cells 
to butyrate is an intriguing observation since it has previously been reported that human T 
cell IL-17 production, unlike IFNγ, is sensitive to GPR43 agonism[301] and thus the low 
frequencies of GPR43+ LP CD4 cells in our cultures may be reflective of the similarly low-
frequency Th17 population.  
To determine if the difference in Th subset sensitivity to butyrate was specific to the 
gut PB Th subsets were similarly tested. In PB Th cells Th17 cells responded to butyrate 
similarly to Th1 and Th22 cells. Interestingly, the non-IFNγ, IL-17, IL-22 producing PB Th 
cells proliferated the least in response to TCR stimulation and were the most sensitive to the 
antiproliferative effects of butyrate. From these data, several possible conclusions can be 
made. First, the magnitude of proliferation in the Th subsets in the PB and LP differ as does 
the sensitivity of these cells to butyrate. This could be the result of intrinsic differences 
between LP and PB Th cells, such as their activation state, or merely differences in the 
ability of these cells to respond to direct TCR stimulation and subsequently to butyrate. At 
this time further mechanistic studies are needed to determine the nature of these differential 
responses to butyrate.  
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 Activated CD4 T cells are readily infected with HIV-1 and depleted in PLWH[286]. 
Therefore, the observation that butyrate decreased LP CD4 T cell activation and 
proliferation in a concentration-dependent manner led to the hypothesis that butyrate would 
similarly decrease HIV-1 infection of LP CD4 T cells due to their decreased activation and 
proliferation. To test this, I used an in vitro model of acute infection of LPMC with a 
transmitted founder virus. Butyrate reduced the frequency of productively infected LP CD4 T 
cells at concentrations ≥ to 0.25mM and increased the frequency of productively infected LP 
CD4 T cells at concentrations ≤0.125mM after four days of infection. This was similarly 
reflected in the frequency of productively infected Th subsets and the production of 
infectious virions. The observation of a differential impact of butyrate at higher and lower 
concentrations is interesting since there appears to be an uncoupling of LP CD4 T cell 
activation and HIV-1 infection in the setting of lower concentrations of butyrate, and an 
activation-independent regulation of HIV-1 infection at these concentrations. To determine if 
the impact of butyrate was mediated by direct action on LP CD4 T cells, the effect of 
butyrate on HIV-1 infection in purified LP CD4 T cells was next assayed.  The data from 
these assays indicated that the impact of butyrate at lower concentrations was indirect, 
while the effect at higher concentrations was direct. 
 Previous studies with enteric bacteria have shown that productive HIV-1 infection 
can be increased significantly in the absence of overt LP CD4 T cell activation through the 
upregulation of the HIV-1 co-receptor CCR5 by other cells in the LPMC[156]. Due to the 
established impact of CCR5 expression on HIV-1 infection, the expression of CCR5, as well 
as CD4, were examined in the setting of TCR stimulation and exogenous butyrate. Similar to 
the trend seen with productive HIV-1 infection, CCR5 expression increased at lower 
concentrations of butyrate ≤0.125mM and but was not affected by higher concentrations. 
Conversely, low concentrations of butyrate did slightly increase the expression of CD4, but 
higher concentrations decreased its expression. These assays were next carried out with 
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purified LP CD4 T cells, which demonstrated that the effect of lower concentrations of 
butyrate on CCR5 expression was dependent on other cell types in the LPMC and the effect 
on CD4 expression was direct. Collectively, these data indicate that at lower concentrations 
of butyrate there is an indirect effect of butyrate that increases CCR5 expression and 
productive HIV-1 infection, while at higher concentrations there is a direct effect of butyrate 
on LP CD4 T cells which decreased CD4 expression and productive HIV-1 infection.  
To determine if the changes in productive infection were due to an increase in viral 
entry and reverse transcription due to increased co-receptor expression or if more HIV-1 
virus was being produced by these cells due to the known effect of HDACi on HIV-1 
transcription[302] qPCR based methods examined viral entry, reverse transcription, and viral 
transcription. The data from these assays indicate there to be a slight increase in HIV-1 viral 
entry or reverse transcription at 0.125mM and no discernable effects at other 
concentrations. Conversely, there appeared to be a concentration-dependent increase in 
viral transcription. These data indicate that there does seem to be an impact on viral entry or 
reverse transcription at the concentrations of butyrate where there were observed increases 
in CCR5 expression and productive infection and that this is independent of changes in viral 
transcription.  The viral transcription data is interesting because the increased relative 
amounts on transcription at 0.5mM do not translate to increased frequencies of productively 
infected LP CD4 T cells or the production of infectious virions. While the mechanism for the 
difference is unknown at this time, there are several possibilities for this observation. First, 
the increase in transcription could be due to the higher relative amounts of HDAC inhibition 
at 0.5mM. This, however, does not translate to differences in productive infection due to the 
substantial decreases in LP CD4 T cell activation, proliferation, and CD4 expression. 
Secondly, the normalization of the data could be affecting the reported values. There is 
higher relative proliferation at the lower concentrations of butyrate which could account for a 
higher amount of GAPDH (housekeeping gene) expressed relative to HIV-1 gag RNA at 
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early timepoint thus resulting in lower reported values. Conversely, at 0.5mM there is a 
substantial decrease in LP CD4 T cell proliferation and therefore likely less GAPDH present 
relative to HIV-1 gag RNA. Collectively, these data indicate that butyrate is altering the HIV-
1 life cycle and further in-depth studies are warranted.     
Potential Implications 
  Collectively, the in vitro data outlined in this thesis suggest that in untreated PLWH, 
low abundances of BPB and therefore likely low concentrations of tissue butyrate may be a 
contributing factor to high levels of viral replication and infection of LP CD4 T cells. This 
process is likely mediated indirectly through butyrate’s impact on other cells (e.g., APCs) to 
drive increased expression of the HIV-1 co-receptor CCR5 and increased viral entry or 
reverse transcription. This is in contrast to what would occur at higher concentrations of 
butyrate, where butyrate would directly decrease LP CD4 T cell activation, likely through 
HDAC inhibition, thus limiting the infection of LP CD4 T cells. It is possible that this scenario 
at higher butyrate concentrations would have the most significant effect on T cells that are 
newly recruited into the gut mucosa and thus limits their subsequent unchecked activation 
and response to translocating dysbiotic bacteria[79, 103, 231, 285] (Figure 6.1). 
In an attempt to link alterations in BPB communities in PLWH and the impact of a 
loss of tissue concentrations of butyrate, I tested the effect of butyrate on LP CD4 T cell 
activation and proliferation. While there is a precedence for butyrate’s ability to alter T cell 
activation and function, these data were the first to demonstrate an immunomodulatory 
effect of butyrate on human gut LP T cells. Translated to a clinical setting these 
observations could have an impact on the management of gut centric inflammatory 
disorders. By increasing butyrate concentrations (within the normal physiologic range) one 
would anticipate that there would be lower levels of T cell activation both in the gut mucosa 
and potentially systemically if blood concentrations increase sufficiently. However, due to 





Figure 6.1 LP CD4 T Cell Activation and HIV-1 Infection are Differentially Impacted by 
Butyrate in a Concentration-dependent Manner. A model that translates our findings into 
what may be occurring in the gut mucosa of PLWH. In short, in the setting of the lower 
abundances of BPB and thus lower tissue butyrate levels, there is a relatively higher amount 
of LP CD4 T cell activation, CCR5 expression, HIV-1 infection, and inflammation. 
Conversely, with higher abundances of BPB and tissue butyrate levels, there is a lower 
relative amount of LP CD4 T cell activation, CD4 expression and subsequent HIV-1 infection 












both the gut mucosa and systemic circulation would likely be beneficial in environments that 
have limited exposure to infectious diseases such as Mycobacterium tuberculosis (mTB). 
This is highlighted by the observations in Segal et al. [303] who demonstrated that increased 
serum concentrations of butyrate and propionate in HIV-1 infected individuals were 
predictive of mTB susceptibility likely due to suppression of Th17 and Th1 responses. 
Therefore, there may be a risk in increasing SCFA concentrations outside of normal ranges 
and caution may be warranted in interventions that increased SCFA concentrations as a 
target in populations susceptible to infectious disease such as PLWH in areas with endemic 
infectious disease.  
 Another important observation made in this thesis is that the antiproliferative effect of 
butyrate on LP CD4 T cells requires butyrate to either be present before TCR stimulation or 
very early after TCR stimulation.  Once the LP CD4 T cells have been activated for at least 
18 hours the antiproliferative capacity of butyrate is diminished. The temporal nature of the 
butyrate response is likely due to the mechanism by which butyrate alters LP CD4 T cell 
proliferation. For example, If HDAC inhibition is responsible for the decreased proliferation 
noted in the presence of butyrate as our model suggests, it is likely that it must be present 
early in the events of T cell activation to alter the capacity of these cells to undergo 
proliferation. This would likely occur via the regulation of gene expression and proteins 
involved in cell cycle (e.g., cyclins) progression. These observations also have clinical 
implications and may explain the inconsistent results of the modulation of butyrate 
concentrations either directly or through probiotic and prebiotic therapies in individuals with 
IBD [261, 293, 294, 304]. Gut mucosal T cell activation is an important feature of HIV-1 
infection and IBD, and it is possible that butyrate interventions would be more efficacious if 
given to individuals who were currently in milder disease states with limited T cell activation 
rather than those with more overt T cell activation. Conversely, if butyrate concentrations are 
increased for an extended period the activation of newly recruited CD4 T cells would likely 
102 
 
be dampened and thus act to limit the severity of the disease. Follow up studies on the 
temporal importance of butyrate addition on HIV-1 infection in our model are also warranted.  
 The majority of the data presented in this thesis examined the impact of butyrate on 
LP CD4 T cell activation and function. However, it is important to note that the other primary 
SCFAs, propionate and acetate, also inhibited LP CD4 T cell activation and proliferation in a 
concentration-dependent manner. These SCFA showed similar activity to butyrate albeit at 
higher concentrations. These data are not surprising since these SCFA share homology in 
the surface GPRs that they signal through (GPR41 and GPR43) and their function as an 
HDACi[228].  Combined with the lack of significant expression of GPR43 on LP CD4 T cells, 
these data strengthen the observation that butyrate, as well as propionate and acetate, are 
likely inhibiting LP CD4 T cell activation and proliferation through HDAC inhibition. These 
observations also indicate that there are redundancies in the effect of these SCFA on LP 
CD4 T cell activation.  Therefore, the decrease in the concentration of one SCFA may be 
compensated for by the presence of the other two, and thus the modulation of total SCFA 
may be important to target in the regulation of gut mucosal T cell activation.  
 One of the most salient observations made in this thesis was that the impact of the 
addition of exogenous butyrate to HIV-1 infected and activated LP CD4 T cells did not result 
in a concentration-dependent decrease in infection. Indeed, lower concentrations of butyrate 
increased the productive infection of LP CD4 T cells likely through increased expression of 
CCR5 and increased viral entry or reverse transcription. The observations that butyrate 
increases HIV-1 while simultaneously decreasing LP CD4 T cell activation are somewhat 
counterintuitive since it is traditionally thought that T cell activation and HIV-1 infection are 
tightly coupled events. The lack of these observations in cultures with purified LP CD4 T 
cells indicates a role for another cell type in the LPMC, such as an mDC, in mediating these 
effects of butyrate. Therefore, it is likely that butyrate is decreasing the activation and 
proliferation of LP CD4 T cells but at a very narrow concentration range also altering the 
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production of proteins such as cytokines in the LPMC fraction to drive increases in LP CD4 
T cell infection. One potential mechanism could be the production of cytokines by bystander 
cells in LPMC. In an endotoxemia model, it has been demonstrated that rhIL-10 treatment of 
PBMCs increased CCR5 expression on human CD4 T cells[289]. Butyrate has also been 
shown to alter the production of IL-10 from myeloid cells and T cells. Thus, it is possible that 
butyrate increases LP CD4 T cell infection at lower concentrations via the indirect 
modulation of cytokines produced in other cell types.  
Limitations and Future Directions 
 There are several limitations to the data presented in this thesis and unanswered 
questions that remain to be addressed. There are limitations of the in vitro model used to 
study the effect of butyrate on gut mucosal T cell function and HIV-1 infection. First, the 
disaggregated nature of the cells used in the model does account for the importance of 
signals from epithelium and IELs that may alter the impact of butyrate on LP CD4 T cell 
function. Secondly, the LPMC are primary cells which are not amenable to genetic 
manipulation in our experience. This makes it challenging to study the importance of specific 
proteins in our model, such as HDAC proteins, by genetic manipulation. Lastly, the LPMC 
infection model reflects an acute HIV-1 infection, which is not directly a limitation but makes 
it more challenging to infer the impact of butyrate in the mucosa of chronically infected 
individuals.   
 The observations outlined in this thesis lay the foundation for a multitude of further 
studies that can be carried out to understand the impact of butyrate on gut mucosa T cell 
function and HIV-1 infection. It would be informative to look at changes in gene networks 
and specific genes in LP CD4 T cells treated with higher and lower concentrations of 
butyrate in the setting or absence of HIV-1 infection and TCR stimulation. This could be 
done by single-cell RNA sequencing of LP CD4 T cells to understand how butyrate is 
altering gene expression in specific Th cell subsets by using Th specific transcription factors 
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(e.g., Tbet) for Th subset identification. Furthermore, carrying out these assays on purified 
LP CD4 T cells and LP CD4 T cells sorted after culture with total LPMC would generate data 
on alterations in gene expression due to a direct effect of butyrate relative to those driven by 
other cell types in the LPMC. If carried out this would be the first assay of its type looking at 
the impact of butyrate specifically on human gut LP CD4 T cells. From these assays, 
hypotheses could be generated to further tease out the specific mechanisms by which 
butyrate alters LP CD4 T cell function. 
Furthermore, key follow up experiments to gene expression assays would likely 
include paired chromatin immunoprecipitation (ChiP) sequencing analysis to evaluate if 
histone modifications associated with the resultant changes in specific gene expression. As 
a follow up to these experiments, the inhibition, either chemically or genetically, of specific 
HDAC proteins could next be studied to elucidate the mechanism of butyrate’s actions 
further.  Taken together, these assays would inform on the mechanisms by which butyrate 
alters LP CD4 T cell function and offer insight into potentially druggable targets to limit HIV-1 
pathogenesis and inflammation.  
 In addition, the use of clinical models would help to better understand the effects of 
butyrate on LP CD4 T cell function and HIV-1 infection and confirm findings from the in vitro 
studies. With the importance of the microbiome in GI tract health and the observation that 
HIV-1 associated dysbiosis may contribute to chronic inflammation and disease progression, 
several studies have sought to determine if modulation of the microbiome by pro- and 
prebiotics are beneficial in PLWH. The results of these studies have been mixed but have 
shown promise[146-151]. One encouraging study in PLWH carried out by Serrano-Villar et 
al. [152] examined the impact of pre-biotics and glutamine (scGOS/lcFOS/glutamine) 
supplementation on the composition of the microbiota and immunological markers in PLWH. 
The results of that study demonstrated that prebiotic supplementation reduced HIV-1 
dysbiosis of the stool microbiota. Also, they noted a decline in peripheral T cell activation, 
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microbial translocation and an increase in butyrate production in individuals in the prebiotic 
treatment arm. Lastly, they noted that increased relative abundance of stool 
Faecalibacterium and Lachnospira associated with increased stool butyrate concentrations 
and lower microbial translocation and systemic inflammation[152]. While these studies are 
promising, they use probiotics and prebiotic supplementation, which are both nonspecific 
interventions and limit the interrogation of the specific pathways involved in the positive 
clinical outcomes. To overcome this, a similar model using a specific butyrate therapy, such 
as orally available butyrate in the form of tributyrin[305],  could be employed in treated and 
untreated PLWH. After exposure to butyrate, frequencies of and activation states of Th 
subsets in the gut mucosa of these individuals could be investigated in mucosal biopsies. 
Furthermore, LP CD4 T cells could be isolated from these individuals and similarly tested on 
a limited scale in the LPMC model outlined in this thesis. Additionally, the investigation of 
specific genes and gene networks identified in the proposed genomics study could be 
investigated in vivo to further confirm butyrate’s mechanism of action on gut mucosal CD4 T 
cells.  
 In summary, the data presented in this thesis offer a foundation to further explore the 
mechanism by which altered concentrations of butyrate in the gut mucosal tissue impact LP 
CD4 T cell activation and HIV-1 disease progression.  Furthermore, alterations in gut 
butyrate concentrations offer an attractive target for therapeutic interventions for PLWH and 
others with inflammatory disorders of the GI tract. While not likely curative, the increase in 
butyrate concentrations in the gut mucosal tissue of PLWH may dampen the negative 
impact of HIV-1 infection in the gut mucosa and limit the chronic immune activation that is 
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Colorado Clinical and Translational Sciences Institute (CCTSI) TL1 Fellowship Clinical 
Experience 
The Colorado Clinical and Translational Sciences Institute (CCTSI) offers several one-
year TL1 fellowships to students carrying out basic science research on the Anschutz Medical 
Campus. This fellowship aims to promote the integration and interface of basic science 
research and clinical medicine at the predoctoral level. As a TL1 fellowship recipient, we were 
expected to attend monthly TL1 journal clubs and guest presentations as well as complete a 
full day of shadowing in the clinic per month. Also, fellowship recipients are required to attend 
the national TL1 meeting and complete required coursework in biostatistics, epidemiology, 
and disease-focused basic science courses. After the completion of the requirements and 
thesis defense, each fellowship recipient will be awarded a certificate acknowledging the 
successful completion of the fellowship.  
As a CCTSI TL1 fellowship recipient for the 2017-2018 year, I completed the following 
course work: Tissue Biology and Disease Mechanisms (IDPT 7646),   Statistics for the Basic 
Sciences (BIOS 6606) and Epidemiology (EPID 6630). As a medical scientist training program 
(MSTP) student I also completed pre-clinical coursework in human anatomy, physiology and 
disease pathophysiology that helped fulfill these coursework requirements. As part of the TL1 
fellowship, I presented my data at the 2018 National TL1 conference in Washington, D.C. in 
the form of a poster titled “The microbial-derived short-chain fatty acid butyrate directly and 
differentially inhibits gut T helper cell subset activation and proliferation.” While at the 
conference, I was able to attend several talks and information sessions about career 
opportunities, networking, and translational science. Also, the conference allowed several 
opportunities for networking with individuals at various career levels, including predoctoral and 
postdoctoral candidates as well as several senior investigators and mentors. One of the most 
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impactful experiences of the conference was the opportunity to go to the offices of the state 
of Colorado representatives in the House and Senate to discuss the importance of 
translational research and continued funding for both the NIH and the TL1 program with them. 
Lastly, my clinical experience was carried out with Dr. Jose Castillo-Mancilla at the University 
of Colorado Hospital in Aurora, Colorado.  
The basis of my thesis project was formed around the observation that during HIV-1 
infection the breakdown of the gut barrier is associated with chronic immune activation which 
is a linked to increased morbidity and mortality[101, 252, 278, 310]. To better understand the 
potential clinical relevance and implications of my thesis project, I was mentored by Dr. José 
Castillo-Mancilla.  Due to the impact of systemic inflammation and immune activation in 
PLWH, the goal of my shadowing experience with Dr. Castillo-Mancilla was to observe him 
during his weekly inpatient clinic, at the University of Colorado Hospital where he currently 
serves a patient population that includes 80 PLWH.  Many of these individuals whom I 
encountered in the clinic had been chronically infected and have several non-AIDS related 
comorbidities such as neurocognitive decline, cardiovascular and metabolic diseases which 
are known to be associated with chronic immune activation and inflammation[101, 252, 278, 
310]. During these shadowing opportunities, I observed Dr. Castillo-Mancilla manage his 
patients’ care and attended the visits of specific patients to gain a better understanding of their 
longitudinal care and how living with HIV-1 inflammation-associated comorbidities impacted 
their daily lives.   
Aside from the clinical challenges that these individuals faced, I was also able to learn 
about their struggles with their diagnosis and the impact that having HIV-1 has had on their 
personal and professional lives. One of my most memorable experiences was interviewing a 
patient who had been living with HIV-1 since the early 1990s. This patient detailed the 
struggles of having HIV-1 before effective ART and the issues that some of the early ART 
regimes had. Also, they recounted losing numerous close friends to the disease as well as 
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their current struggles with conditions linked to chronic inflammation such as their struggle 
with metabolic and cardiovascular disease. While I had understood the clinical progression of 
HIV-1 and the associated comorbidities, listening to an individual who had struggled with this 
disease for over twenty years, put the importance not only my work but all of the work in the 
HIV-1 field into perspective.  Moreover, this exposure will help tailor my research goals to be 
translationally relevant to the treatment and care those struggling with chronic HIV-1 infection 
and to be a proficient and understanding physician-scientist by not only understanding the 
scientific issues that need to be addressed to combat this disease but also the human 
connection required to provide adequate care. 
